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Abstract	  	   Soluble	   epoxide	   hydrolase	   (sEH)	   is	   an	   enzyme	  with	  multiple	   functions	  that	  has	  two	  distinct	  enzyme	  activities:	  epoxide	  hydrolase	  (C-­‐terminal	  domain)	  and	  phosphatase	  (N-­‐terminal	  domain).	  The	  endogenous	  substrates	  of	  epoxide	  hydrolase	  are	  epoxyeicosatrienoic	  acids	  (EETs)	  that	  are	  hydrolyzed	  by	  sEH	  to	  corresponding	   diols,	   dihydroxyeicosatrienoic	   acids	   (DHETs).	   The	   N-­‐terminal	  domain	  metabolizes	  lysophosphatidic	  acids	  (LPAs).	  In	  this	  study,	  I	  investigated	  the	  catalytic	  activity	  of	  sEH	  isolated	  from	  Xenopus	  laevis	  and	  the	  metabolism	  of	  lysophosphatidic	   acids	   (LPAs)	   by	   allelic	   variants	   of	   human	   sEH.	   Firstly	   the	  catalytic	   activities	   of	   both	   N/C	   terminal	   domains	   of	   sEH	   were	   investigated.	  
Xenopus	  sEH	  cDNA	  was	  isolated	  from	  embryos	  of	  Xenopus	  laevis.	  The	  Xenopus	  sEH	  was	  expressed	  in	  Escherichia	  coli	  and	  was	  purified.	  The	  purified	  Xenopus	  sEH	   did	   not	   show	   phosphatase	   activity	   toward	   4-­‐methylumbelliferyl	  phosphate	   (4-­‐MUP)	  or	   several	  LPAs	  although	   it	  had	  EH	  activity.	  The	  epoxide	  hydrolase	   activity	   of	   sEH	   seemed	   to	   be	   similar	   to	   that	   of	   human	   sEH,	  while	  
Xenopus	  sEH	  did	  not	  have	  phosphatase	  activity	  toward	  several	  substrates	  that	  human	  sEH	  metabolizes.	  In	  contrast,	  to	  elucidate	  the	  sEH	  phosphatase	  activity	  that	  metabolizes	  LPAs,	   the	  human	  sEH	  were	  used.	  A	  purified	  wild-­‐type	  (WT)	  and	   six	   allelic	   variants	   of	   sEH	   (K55R,	   R103C,	   C154Y,	   R287Q,	   V422A,	   and	  E470G)	   were	   used	   in	   this	   study.	   The	   R103C	   and	   R287Q	   variants	   revealed	  significant	  lower	  activity	  than	  WT	  sEH.	  The	  kinetic	  study	  indicated	  that	  R103C	  and	  R287Q	  variants	  had	  lower	  Vmax/Km	  ratio	  toward	  stearoyl-­‐LPA	  than	  other	  variants.	   Regarding	   the	   effect	   of	   sEH	   allelic	   variants	   on	  VEGF	   expression,	   all	  variants	  except	  V442A	  revealed	  suppressed	  VEGF	  mRNA	  levels	  in	  Hep3B	  cells.	  These	   results	   suggest	   that	   the	   R103C	   and	   R287Q	   variants	   have	   lower	  phosphatase	   activity,	   however,	   all	   allelic	   variants	   except	  V442A	  have	   similar	  effect	  to	  the	  VEGF	  suppression.	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General	  Introduction	  
	   sEH	  enzymes	  are	  widely	  present	  in	  all	  living	  organisms,	  such	  as	  mammal,	  bacteria,	   yeast,	   and	   fungi.	   The	   sEH	   enzyme	   plays	   a	   significant	   role	   in	   the	  detoxification,	  catabolism,	  and	  regulation	  of	  signaling	  molecules.	  sEH	  has	  two	  domains:	  N-­‐terminal	  phosphatase	  domain	  and	   	  C-­‐terminal	  epoxide	  hydrolase	  domain.	   The	   C-­‐terminal	   domain	   is	   connected	   via	   a	   proline-­‐rich	   linker	   to	   a	  smaller	  N-­‐terminal	  domain.	  The	  C-­‐terminal	  epoxide	  hydrolase	  catalytic	  activity	  has	  been	  well	  studied.	  The	  epoxide	  hydrolase	  (EH)	  are	  enzymes	  that	  catalyze	  the	  hydrolysis	  of	   exogenous	  and	  endogenous	  epoxide	   to	   their	   corresponding	  diols	   by	   addition	   of	   water.	   The	   C-­‐terminal	   epoxide	   hydrolase	   sequences	   are	  member	   of	   the	   α/β	   hydrolase	   fold	   superfamily.	   In	   the	   C-­‐terminal	   domain,	  D335,	   D496,	   and	   H524	   are	   catalytic	   active	   sites	   that	   are	   together	   called	   the	  catalytic	   triad	   for	   epoxide	   hydrolase	   activity	   	  1).	   In	   contrast,	   a	   function	   of	   N-­‐terminal	   phosphatase	   that	   has	   high	   homology	   to	   the	   haloacid	   dehalogenase	  family	  of	  phosphatases,	  remain	   less	  studied.	   In	  this	  study,	  characterization	  of	  sEH	  catalytic	  activity	  of	  Xenopus	  laevis	  was	  investigated.	  On	  the	  other	  hand,	  the	  mutated	  residues	  of	  human	  sEH	  allelic	  variants	  were	  examined	  to	  understand	  the	   effect	   of	   these	   variants	   on	   the	   metabolism	   of	   lysophosphatidic	   acids	  (LPAs).	  These	   investigations	  may	  useful	   for	   further	  clarifying	   the	  role	  of	   sEH	  phosphatases	  functions.	  	   The	   endogenous	   substrate	   of	   EH	   is	   epoxyeicosatrienoic	   acids	   (EETs).	  EETs	   are	   generated	   by	   the	   activity	   of	   both	   selective	   and	   also	   more	   general	  cytochrome	  p450	  (CYP)	  enzymes	  on	  arachidonic	  acid	  and	   inactivated	   largely	  by	  sEH,	  which	  converts	   them	  to	   their	   corresponding	  dihydroxyeicosatrienoic	  acids	   (DHETs).	   The	   biological	   effects	   of	   EETs	   are	   terminated	   through	   its	  metabolism	  by	  sEH	  to	  DHETs.	  sEH	  is	  largely	  critical	  in	  the	  control	  of	  EET	  levels	  because	  of	  its	  ability	  to	  catalyze	  the	  degradation	  of	  EETs	  into	  diols	   	  2).	  In	  mice	  and	   Zebrafish,	   inactivation	   of	   sEH	   decreased	   progenitor	   cell	   proliferation	   	  3).	  On	   the	   other	   hand,	   in	   previous	   study	   LPAs	   found	   to	   be	   the	   endogenous	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substrates	   for	   the	   phosphatase	   activity	  4).	   Isoprenoid	   phosphatase	   was	   also	  found	   to	   be	   a	   phosphatase	   substrate	   of	   sEH	   	  5).	   Several	   lines	   of	   evidence	  indicate	  a	  biological	  role	  for	  sEH	  phosphatase	  activity	  (N-­‐terminal	  domain).	  In	  mice,	   it	   seems	   that	   the	  N-­‐terminal	  domain	  play	  a	   role	   in	   the	  development	  of	  hypoxia-­‐induced	   pulmonary	   hypertension	   	  6).	   In	   this	   study,	   the	  characterization	   of	   important	   phosphatase	   activity	   in	   Xenopus	   sEH	   was	  evaluated	  by	  the	  comparison	  with	  human	  sEH.	  	  	   In	  comparison	  with	  mammal	  sEH,	   little	   is	  known	  about	   sEH	  of	  Xenopus	  
laevis.	  Xenopus	   sEH	   displays	   high	   homology	   to	   the	   C-­‐terminal	   domain	   of	   the	  human	   sEH	   that	   contains	   the	   amino	   acid	   residue	   critical	   to	   catalytic	   activity.	  However,	  several	  residues	  of	  catalytic	  active	  site	  on	  the	  N-­‐terminus	  of	  human	  sEH	   is	   not	   conserved	   in	   Xenopus	   sEH.	   The	   previous	   investigation	   in	   animal	  models	   showed	   sEH	   catalytic	   activity	   in	   the	   sea	   urchin	   (Strongylocentrotus	  
purpuratus)	   	  7),	   Caenorhabditis	   elegans	   	  8),	   and	   chicken	   (Gallus	   gallus)	   	  7).	  However,	  the	  EH	  and	  phosphatase	  activities	  in	  frog	  sEH	  were	  not	  investigated.	  In	   Chapter	   I,	   the	   isolation	   and	   characterization	   of	   Xenopus	   sEH	  will	   provide	  information	  on	   the	  role	  of	  sEH	  enzymatic	  activity.	  For	  our	  knowledge,	   this	   is	  the	  first	  study	  to	  characterize	  Xenopus	  sEH.	  	   In	  mammalian	  sEH,	  single	  nucleotide	  polymorphisms	  (SNPs)	  of	  sEH	  were	  found	   and	   several	   allelic	   variants	   displays	   different	   epoxide	   hydrolase	  activity	   	  9,10).	   Most	   of	   the	   biological	   roles	   of	   sEH	   allelic	   variants	   have	   been	  attributed	  to	  its	  more	  well	  defined	  on	  EH	  activity.	  Endogenous	  EH	  substrates	  include	  arachidonic	  acid	  and	  linoleic	  acid	  epoxide,	  which	  have	  been	  shown	  to	  regulated	   blood	   pressure	   	  11)	   	   and	   inflammation	   	  12).	   The	   R103C	   amino	   acid	  substitution	   was	   associated	   with	   increased	   cell	   death	   induced	   in	   cortical	  neuron	   by	   oxygen-­‐glucose	   deprivation	   and	   re-­‐oxygenation	   	  13).	   The	   R287Q	  variant	   is	   associated	   with	   increased	   plasma	   cholesterol	   levels	   in	   familial	  hypercholesterolemia	   	  14),	   the	  onset	  on	  coronary	  artery	  calcification	  in	  Africa-­‐American	  individuals	  	  15),	  and	  insulin	  resistance	  in	  type	  2	  diabetic	  	  16).	  However,	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the	  effect	  of	  allelic	  variants	  of	  human	  sEH	  on	  the	  phosphatase	  activities	  toward	  other	  LPAs	  remains	  unknown.	   In	  Chapter	   II,	   the	  catalytic	  activities	  of	  human	  sEH	  allelic	  variants	  were	  examined	  to	  understand	  the	  effect	  of	   these	  variants	  on	  the	  metabolism	  of	  LPAs.	  	   LPA	   is	   a	   bioactive	   phospholipid	   with	   diverse	   physiological	   action	   on	  many	  of	  cells	  types.	  LPA	  signaling	  are	  large	  views	  on	  the	  potential	  pathway	  in	  human	   diseases	   that	   include	   cardiovascular	   and	   cancer	   	  17,18).	   Previously	   we	  found	   the	   LPAs	   are	   endogenous	   substrate	   of	   sEH.	   In	   addition,	   phosphatase	  domain	   contributed	   to	   the	   expression	   of	   vascular	   endothelial	   growth	   factor	  (VEGF)	  and	  cell	  growth	  	  19).	  The	  variants	  R103	  and	  R287	  of	  sEH	  are	  promising	  research	  area	  in	  the	  direction	  of	  signaling	  molecule	  associated	  with	  the	  human	  diseases	   such	   as	   cardiovascular	   and	   cancer.	   In	   the	   present	   experiment,	   six	  allelic	   variants	   of	   sEH	  were	   expressed	   in	   the	  Hep3B	   cells	   to	   understand	   the	  effect	   of	   these	   variants	   on	   VEGF	   suppression.	   The	   major	   disease	   areas	  associated	  with	  LPA	  as	  described	  above	  and	  sEH	  allelic	  variant	  may	  reveal	  a	  linkage	  between	  LPA	  and	  phosphatase	  activity.	  	  In	  Chapter	  II,	  the	  action	  of	  sEH	  on	   several	   LPAs	   could	   explain	   the	   biological	   functions	   associated	   with	   the	  phosphatase	   activity.	   The	   metabolism	   of	   LPA,	   phosphatases,	   and	   sEH	   allelic	  variant	  might	  contribute	   to	  provide	  new	   insight	  on	   the	   role	  of	   this	  matter	   in	  the	  near	  future.	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I.1	  Introduction	   	  	   Soluble	   epoxide	  hydrolase	   (sEH)	   is	   a	   ubiquitous	   enzyme	   in	   vertebrates	  that	  transform	  epoxides	  to	  their	  corresponding	  diols	  	  20,21).	  Human	  sEH	  has	  555	  amino	   acid	   residues	   containing	   N-­‐terminal	   and	   C-­‐terminal	   domains.	   The	   N-­‐terminal	   domain	   has	   1-­‐209	   amino	   acid	   residues	   and	   the	   C-­‐terminal	   domain	  has	   217-­‐555	   amino	   acid	   residues.	   The	   C-­‐terminal	   domain	   is	   connected	   via	   a	  proline-­‐rich	   linker	   to	   a	   smaller	   N-­‐terminal	   domain.	   sEH	   has	   two	   distinct	  enzyme	   activities:	   N-­‐terminal	   phosphatase	   activity	   and	   	   C-­‐terminal	   epoxide	  hydrolase	  activity	  	  6,22).	  In	  the	  N-­‐terminal	  domain,	  a	  substitution	  of	  D11,	  T123,	  N124	  or	  D185	  leads	  to	  sEH	  mutant	  protein	  having	  altered	  kinetic	  properties.	  In	  contrast,	  substitution	  of	  D9,	  K160,	  D184	  or	  N189	  resulted	  in	  a	  complete	  loss	  of	   phosphatase	   activity	   consistent	   with	   an	   essential	   function	   for	   catalytic	  activity	   	  23).	   In	   the	   C-­‐terminal	   domain,	   D335,	   D496,	   and	   H524	   are	   catalytic	  active	   sites	   that	   are	   together	   called	   the	   catalytic	   triad	   for	   epoxide	   hydrolase	  activity	   	  1).	  The	  catalytic	  activity	  of	  human	  sEH	  has	  been	  found	  and	  explained	  by	   the	   action	   of	   the	   C-­‐terminal	   domain	   alone.	   Therefore,	   the	   recombinant	  human	   sEH	   lacking	   the	   C-­‐terminal	   domain	   also	   displays	   phosphatase	  activity	   	  6,24).	   Mammalian	   soluble	   epoxide	   hydrolase	   consisting	   of	   EH	   and	  phosphatase	  domain	   is	   though	   to	  be	  a	  product	  of	   the	   fusion	  of	   two	  ancestral	  bacteria:	  haloalkane	  dehalogenase	  and	  haloacid	  dehalogenase.	  The	  N-­‐terminal	  domain	  of	   sea	  urchin	   (Strongylocentrotus	  purpuratus)	   lacks	   residues	   thought	  to	   be	   important	   for	   sEH	   phosphatase	   activity	   	  7).	   No	   predicted	   enzymes	  correspond	   to	   full-­‐length	   sEH	   in	   the	   genome	   of	   Caenorhabditis	   elegans	   	  8).	  Chicken	  (Gallus	  gallus)	  sEH	  has	  high	  homology	  of	  the	  N-­‐terminal	  domain	  with	  the	  human	  sEH	  but	  lack	  phosphatase	  activity	  	  7).	  However,	  EH	  and	  phosphatase	  activities	   in	   amphibian	   sEH	   were	   not	   investigated.	   In	   this	   study,	   the	  characterization	   of	  Xenopus	  sEH	  will	   provide	   information	   on	   the	   role	   of	   sEH	  enzymatic	  activity.	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   sEH	   is	   a	   key	   enzyme	   in	   the	   metabolic	   conversion	   or	   degradation	   of	  epoxyeicosatrienoic	  acids	   	  25)	  which	  are	  produced	  by	  cytochrome	  P450	  (CYP)	  epoxygenase	   from	   arachidonic	   acid	   	  25,26).	   The	   biological	   effects	   of	   EETs	   are	  terminated	   through	   its	   metabolism	   by	   sEH	   to	   dihydroxyeicosatrienoic	   acids	  (DHETs),	  a	  process	   that	  serves	  as	  a	  key	  regulator	  of	   tissue	  EET	   levels	   	  27).	   	   In	  mice,	   sEH	   inactivation	   attenuated	   progenitor	   cell	   proliferation	   but	   the	   sEH	  products	   12,	   13-­‐dihydroxyoctadacenoic	   acid	   (12,	   13-­‐DiHOME)	   and	   11,	   12-­‐dihydroxyeicosatrienoic	  acid	  stimulated	  canonical	  Wnt	  signaling	  and	  rescued	  the	   effect	   of	   sEH	   inhibition.	   In	   Zebrafish,	   sEH	   downregulation/inhibition	  impaired	  the	  development	  of	  the	  caudal	  vein	  plexus	  and	  decreased	  the	  number	  of	  progenitor	  cells	  	  3).	  	  	   Previously	  it	  was	  found	  that	  lysophosphatidic	  acids	  (LPAs)	  are	  substrates	  for	  the	  phosphatase	  activity	  of	  human	  sEH	  	  4).	  Isoprenoid	  phosphatase	  was	  also	  found	  to	  be	  a	  substrate	  of	  sEH	  	  5).	  Several	  lines	  of	  evidence	  indicate	  a	  biological	  role	  for	  sEH	  phosphatase	  activity	  (N-­‐terminal	  domain).	  The	  sEH-­‐null	  mice	  that	  lack	  both	  epoxide	  hydrolase	  and	  phosphatase	  activities	  have	  lower	  cholesterol	  and	  steroid	  levels	  	  28).	  In	  mice,	  it	  seems	  that	  the	  N-­‐terminal	  domain	  play	  a	  role	  in	   the	   development	   of	   hypoxia-­‐induced	   pulmonary	   hypertension	  6).	  Furthermore,	  our	  previous	   study	   found	   the	  phosphatase	  domain	  contributed	  to	   the	   expression	   of	   vascular	   endothelial	   growth	   factor	   (VEGF)	   and	   cell	  growth	  	  19).	  	  	   The	   aim	   of	   this	   study	   is	   to	   clarify	   the	   characterization	   of	   Xenopus	   sEH	  catalytic	   activity.	   To	   our	   knowledge,	   this	   is	   the	   first	   study	   to	   characterize	  
Xenopus	  sEH.	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I.2	  Materials	  and	  methods	  
Eggs	  and	  embryos	  of	  Xenopus	  laevis	  	   Eggs	   were	   obtained	   from	   female	   Xenopus	   laevis	   (Watanabe	   Zoushoku,	  Hyogo,	  Japan)	  by	  human	  chorionic	  gonadotropin	  injection.	  Eggs	  were	  raised	  in	  chestnuts	  suspended	  in	  1.0	  x	  Modified	  Birth’s	  Solution	  (MBS),	  0.5	  mM	  HEPES,	  pH	  7.5,	  containing	  10	  mM	  NaCl,	  0.2	  mM	  KCl,	  0.1	  mM	  MgCl2,	  0.2	  mM	  CaCl2.	  The	  chestnuts	   were	   isolated	   from	   a	   male	   by	   surgical	   operation.	   The	   fertilized	  embryos	  were	  dejellied	  using	  2%	  cysteine	  and	  washed	  with	  0.1	  x	  MBS	  several	  times.	   Embryos	   were	   staged	   according	   to	   Nieuwkoop	   and	   Feber’s	   normal	  table	  	  29).	  The	  embryos	  were	  cultured	  in	  60	  mm	  glass	  dishes	  containing	  15	  mL	  medium	  at	  180C.	  	  
Isolation	  of	  RNA	  and	  Reverse	  transcription-­‐PCR	  	  Total	  RNA	  was	  extracted	  from	  eggs	  at	  various	  stages	  (0,	  10.5,	  18,	  23,	  26,	  30	   and	   38)	   and	   converted	   to	   cDNA	   using	   reverse	   transcriptase	   (Fermentas,	  Burlington,	  Ontario,	   Canada)	   according	   to	   the	  manufacturer’s	   instructions	   as	  follows:	   incubation	   at	   250C	   for	   15	  min	   and	   at	   420C	   for	   60	  min,	   followed	   by	  heating	   at	   700C	   for	   10	  min.	   The	   DNA	   sequences	   of	   the	   primers	   used	   in	   this	  study	   are	   shown	   in	   Table	   I-­‐1.	   PCR	  was	   performed	  with	   primers	   1	   and	   2	   for	  
Xenopus	   sEH	   and	   with	   primers	   3	   and	   4	   for	   histone-­‐H4	   under	   the	   following	  conditions:	  denaturation	  at	  940C	  for	  2	  min	  and	  27	  and	  23	  cycles,	  respectively,	  940C	   for	  30	   sec,	   550C	   for	  30	   sec,	   and	  720C	   for	  30	   sec.	  The	   reaction	  mixtures	  contained	   10	   pmol	   specific	   primers	   and	   Go	   Taq	   Green	   Master	   Mix	   was	  acquired	  from	  Promega	  (Madison,	  WI).	  DNA	  fragments	  were	  separated	  on	  an	  agarose	   gel	   and	   visualized	   with	   ethidium	   bromide	   staining.	   Bands	   of	   gel	  images	   were	   quantified	   by	   Scion	   Image	   software	   version	   4.03	   (National	  Institutes	  of	  Health,	  Bethesda,	  MD).	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Detection	  of	  Xenopus	  sEH	  mRNA	  in	  various	  tissues	  and	  embryos	  Expression	   of	   Xenopus	   sEH	   mRNA	   was	   detected	   by	   RT-­‐PCR	   at	   various	  
Xenopus	   embryo	   stages	   and	   in	   several	   tissues.	   Tissues	   were	   collected	   from	  brain,	   heart,	   liver,	   lung,	   kidney,	   eye,	   pancreas	   and	   spleen	   of	   adult	   Xenopus.	  Total	  RNA	  was	  extracted	   from	  the	   tissues	  and	  converted	   to	  cDNA	  by	  reverse	  transcriptase	   reaction	   as	   described	   above.	   PCR	  was	   performed	   by	   the	   same	  method	  described	  above.	  	  	  
Whole-­‐mount	  in	  situ	  hybridization	  	   Whole-­‐mount	   in	   situ	   hybridization	   (WISH)	  was	   performed	  using	   albino	  
Xenopus	   embryos	   at	   stage	   18	   (middle	   neurula).	   Thirty	   embryos	   were	   fixed	  with	  fully	  dehydrated	  ethanol.	  A	  DNA	  fragment	  for	  the	  probe	  was	  constructed	  by	  primers	  5	  and	  6.	  PCR	  was	  performed	  as	  follows:	  denaturation	  at	  940C	  for	  3	  min,	  then	  30	  cycles	  of	  940C	  for	  1	  min,	  520C	  for	  2	  min,	  and	  680C	  for	  1	  min.	  The	  amplified	  Xenopus	  sEH	  cDNA	   fragment	   included	  887	  bp	  nucleotides	   and	  was	  ligated	  into	  pBluescripIISK+	  vector.	  The	  sense	  probe	  for	  sEH	  was	  prepared	  by	  linearization	  with	  HindIII	  and	  transcribed	  with	  T3	  RNA	  polymerase.	  The	  anti-­‐sense	   probe	   for	   sEH	   was	   prepared	   by	   linearization	   with	   BamHI	   and	   by	  transcription	   with	   T7	   RNA	   polymerase.	   This	   probe	   was	   hybridized	   and	  visualized	   according	   to	   the	   protocol	   for	   Roche	   Diagnostics	   DIG	   with	   minor	  modification	   	  30,31).	   Images	   of	   in	   situ	   hybridizations	   were	   taken	   using	   an	  Olympus	   SZX16	   Stereo	   Microscope	   equipped	   with	   an	   Olympus	   DP71	  microscope	  digital	  camera.	  	  	  
Isolation	  of	  Xenopus	  sEH	  cDNA	  and	  preparation	  of	  sEH	  mutant	  	   Full-­‐length	  Xenopus	  sEH	  cDNA	  was	  isolated	  by	  PCR	  using	  primers	  7	  and	  8	  in	   Table	   I-­‐1.	   These	   primers	   were	   designed	   from	   the	   nucleotide	   sequence	  reported	   as	  Xenopus	   sEH	   (GenBank	   accession	   no.	   NM_001093674).	   PCR	  was	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performed	  using	  cDNA	  synthesized	  from	  total	  RNA	  of	  Xenopus	  tailbud	  embryos	  (st.38)	  with	  GeneAmp	  high	  fidelity	  Taq	  DNA	  polymerase:	  denaturation	  at	  940C	  for	  3	  min,	  then	  30	  cycles	  of	  940C	  for	  1	  min,	  550C	  for	  2	  min,	  and	  680C	  for	  1	  min.	  The	   amplified	   sEH	   cDNA	   included	   1683	   bp	   nucleotides,	   from	   which	   the	  deduced	  protein	  had	  an	  open	  reading	   frame	  of	  561	  amino	  acid	  residues.	  The	  amino	  acid	  sequence	  deduced	  from	  the	  DNA	  sequence	  of	  the	  isolated	  Xenopus	  
sEH	  cDNA	  in	  this	  study	  was	  found	  to	  have	  two	  amino	  acid	  substitutions,	  Thr	  to	  Asn	  at	  29	  and	  Arg	  to	  His	  at	  146	  (N29T/H146R),	  compared	  with	  the	  amino	  acid	  sequence	  of	  Xenopus	  sEH	  reported	  in	  GenBank	  (accession	  no.	  NM_001093674).	  The	   nucleotide	   sequences	   of	   several	   cDNAs	   from	   different	   individuals	   were	  analyzed	  and	   found	   to	  have	   same	   substitution.	  Therefore,	   it	  may	  be	   a	  native	  mutation.	  The	  clone	  of	  Xenopus	  sEH	  cDNA	  reported	  in	  GenBank	  was	  prepared	  by	  substitution	  of	  N29T/H146R.	  	  
Table	  I-­‐1.	  Primers	  used	  in	  this	  study.	  
	  
	  Primer	  No.	   	  Sequences	  of	  primers	   	  	  1	   	  5’-­‐CGGGATAACATTCAGGGTATCACT-­‐3’	  2	   5’-­‐ATCCATGGCGGTAACTGTCTTCCT-­‐3’	  3	   5’-­‐GGTTGTAGAGTCGTGTCGTA-­‐3’	  	  4	   5’-­‐CTCCAGGAATACCAACTCTC-­‐3’	  5	   5’-­‐GGAATTCCATATGGCTGGGAAGCGCTTCGT-­‐3’	  6	   5’-­‐AAGGATCCATGGCTTCCCAGAGAGTT-­‐3’	  7	   5’-­‐GGAATTCCATATGGCTGGGAAGCGCTTCGT-­‐3’	  8	   5’-­‐TGCAAGCTTCAGTTTGGATGTTACGGGCA-­‐3’	  9	   5’-­‐TTAATACGACTCACTATAGG-­‐3’	  10	   5’-­‐GGGAGATGTAGGCTAGTTTCTAGCCGTTGAA-­‐3’	  11	   5’-­‐TAGCCTACATCTCCCCAGTG-­‐3’	  12	   5’-­‐TCTGCAACAAACTTGGAGAA-­‐3’	  13	   5’-­‐TTCTCCAAGTTTGTTGCAGA-­‐3’	  14	   5’-­‐ACCAGGTCAAAATGGCGACTTAGTGAAGAGA-­‐3’	  15	   5’-­‐CCATTTTGACCTGGTTGTAG-­‐3’	  16	   5’-­‐CTCCAGGAATACCAACTCTC-­‐3’	  17	   5’-­‐TTAATACGACTCACTATAGG-­‐3’	  18	   5’-­‐CTCCAGGAATACCAACTCTC-­‐3’	  19	   5’-­‐GGGGTCCTGCTCACCCCTGGG-­‐3’	  20	   5’-­‐CTTCCAGGAATACCAACTCTC-­‐3’	  21	   5’-­‐TTAATACGACTCACTATAGG-­‐3’	  22	   5’-­‐TTCAATCAACGGAACTCCGGTCACTTTCTC-­‐3’	  23	   5’-­‐GAGAAAGTGACCGGAGTTCCGTTGATTGAA-­‐3’	  24	   5’-­‐TGATGATGATGCGGCCGCCAGTTTGGATGTTACGGGCAAGTTA-­‐3’	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Fragment	  I	  was	  amplified	  by	  PCR	  with	  primers	  9	  and	  10	  and	  fragment	  II	  with	  primers	   11	   and	   12.	   Fragment	   III	   was	   amplified	   using	   primers	   13	   and	   14.	  Fragment	   IV	  was	   amplified	   using	   primers	   15	   and	   16.	   To	   obtain	   fragment	   V,	  fragments	  I	  and	  II	  was	  used	  as	  templates	  with	  primers	  17	  and	  13.	  Fragment	  VI	  was	  made	  using	  fragments	  III	  and	  IV	  with	  primers	  17	  and	  12.	  The	  last	  step	  was	  to	  obtain	  mutant	  1	  by	  fragments	  V	  and	  VI,	  used	  as	  templates	  with	  primers	  18	  and	   12.	   By	   comparing	   our	   Xenopus	   sEH	   with	   human	   sEH,	   I	   found	   that	   Asp	  residues	  at	  11	  were	  substituted	  by	  Gly,	  which	  is	  an	  active	  site	  of	  phosphatase,	  and	   sEH	  G11D	  was	   designated	   xsEH	  mutant	   2.	   PCR	  with	   primers	   19	   and	   20	  was	  carried	  out	  as	  above.	  A	  chimera,	  having	  a	  phosphatase	  domain	  of	  human	  sEH	   and	   epoxide	   hydrolase	   domain	   of	   Xenopus	   sEH,	   was	   also	   prepared.	  Primers	  for	  the	  phosphatase	  domain	  (primers	  21	  and	  22)	  amplifies	  fragments	  corresponding	   to	   human	   sEH	   amino	   acids	   1-­‐334.	   Primers	   for	   epoxide	  hydrolase	  domain	  (primers	  23	  and	  24)	  amplifies	   fragments	  corresponding	  to	  
Xenopus	  sEH	  amino	  acids	  334-­‐563.	  To	  combine	  both	  of	  these	  domains,	  primers	  21	   and	   24	   were	   used	   to	   amplify	   fragments.	   All	   fragments	   were	   ligated	   into	  pET-­‐21a(+)	  (Novagen).	  	  	  
Purification	  of	  Xenopus	  sEH	  	   Full-­‐length	  cDNAs	  of	  Xenopus	  wild-­‐type,	  mutant	  1,	  mutant	  2	  and	  chimera	  sEH	  were	   subcloned	   into	   pET-­‐21a(+)	   vector	   with	  BamHI	   and	   XbaI	   enzymes	  sites	   (Takara	   Bio,	   Shiga,	   Japan).	   The	   recombinant	   His-­‐tagged	   sEH	   proteins	  expressed	   in	   E.	   coli,	   BL21-­‐CodonPlus	   (DE3)	   (Stratagene,	   La	   Jolla,	   CA)	   were	  purified	   with	   a	   Ni-­‐NTA	   agarose	   column	   (Qiagen,	   Hilden,	   Germany).	   The	  purified	  proteins	  were	  dialyzed	   in	  10	  mM	  Tris	  Buffer,	   pH	  7.5,	   overnight	   and	  their	  concentrations	  were	  measured	  with	  the	  Bradford	  method	  (Protein	  Assay,	  Bio-­‐Rad,	  Hercules,	  CA).	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Assay	  of	  epoxide	  hydrolase	  activity	  	   Epoxide	   hydrolase	   activity	   of	   sEH	   was	   measured	   using	   a	   fluorescent	  substrate,	   3-­‐phenyl-­‐cyano	   (6-­‐methoxy-­‐2-­‐naphthalenyl)	   methyl	   ester-­‐2-­‐oxiraneacetic	   acid	   (PHOME)	   purchased	   from	   Cayman	   Chemical	   (Ann	   Arbor,	  MI).	  Purified	  Xenopus	   sEH	  and	  human	  sEH	  (0.5	  µg)	  were	  reacted	  with	  25	  µM	  PHOME	   in	   25	   mM	   Bis	   Tris-­‐HCl,	   pH	   7.0,	   containing	   0.01%	   Bovine	   Serum	  Albumin	   (BSA).	   The	   effect	   of	   pH	   on	   EH	   activity	  was	   evaluated	  with	   Bis	   Tris	  buffer	  (pH	  5.5-­‐7.5).	  The	  effect	  of	  ionic	  strength	  was	  evaluated	  with	  10,	  25,	  50,	  and	  100	  mM	  Bis	  Tris	  buffer	  (pH	  7.0).	  The	  catalytic	  activity	  of	  purified	  Xenopus	  sEH	   and	   human	   sEH	  was	   investigated	   for	   temperatures	   ranging	   from	   20	   to	  370C.	  For	  inhibition	  assay,	  Xenopus	  sEH	  or	  human	  sEH	  was	  incubated	  with	  25	  µM	   PHOME	   in	   25	   mM	   Bis	   Tris	   buffer,	   pH	   7.0,	   containing	   0.01%	   BSA	   in	   the	  absence	   or	   presence	   of	   0	   to	   0.2	   µM	  of	  N,	  N’-­‐dicyclohexyl	   urea	   (DCU)	   (Wako,	  Osaka,	   Japan).	   Fluorescence	   of	   the	   reaction	   product,	   6-­‐methoxy-­‐2-­‐naphthaldehyde	   (6-­‐MNA),	   was	   measured	   every	   5	   min	   for	   60	   min	   by	   the	  EnVision	  2104	  Multilabel	  Reader	  (Perkin	  Elmer,	  Waltham,	  MA)	  at	  an	  excitation	  wavelength	   of	   330	   nm	   and	   an	   emission	  wavelength	   of	   465	   nm	   at	   300C.	   The	  concentration	  of	  6-­‐MNA	  produced	  by	  sEH	  was	  determined	  with	  a	  calibration	  curve	  prepared	  with	  authentic	  6-­‐MNA.	  	  
Assay	  of	  phosphatase	  activity	  	   Phosphatase	   activity	   was	   measured	   using	   4-­‐Methylumbelliferyl	  Phosphate	  (Wako,	  Osaka,	  Japan)	  in	  25	  mM	  Bis	  Tris	  buffer,	  pH	  7.0,	  containing	  1	  mM	  MgCl2	   and	   0.01%	   BSA.	   The	   reaction	   was	   started	   by	   the	   addition	   of	   the	  enzyme,	   purified	   Xenopus	   sEH	   or	   human	   sEH	   (5.0	   µg).	   The	   effects	   of	   ionic	  strength,	  pH	  and	  temperature	  were	  assessed	  as	  described	  above.	  The	  reaction	  was	  performed	  at	  370C	  for	  up	  to	  60	  min	  and	  the	  fluorescence	  intensity	  of	  the	  produced	  4-­‐methylumbelliferone	  was	  measured	  every	  5	  min	  by	  the	  EnVision	  2104	  Multilabel	  Reader	  at	  an	  excitation	  wavelength	  of	  330	  nm	  and	  an	  emission	  wavelength	  of	  465	  nm.	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Phosphatase	  assay	  of	  Xenopus	  sEH	  using	  malachite	  green	  	   The	   phosphatase	   activity	   of	   sEH	   toward	   LPA	   (stearoyl	   L-­‐α-­‐lysophosphatidic	   acid	   (1-­‐octadecanoyl-­‐sn	   glycerol-­‐3-­‐phosphate)	   sodium	   salt)	  (Avanti	  Polar	  Lipids,	  Birmingham,	  AL)	  was	  detected	  by	  the	  Biomol	  green	  assay	  (Enzo	   Life	   Science,	   Plymouth	   Meeting,	   PA)	   according	   to	   the	   manufacturer’s	  instructions.	   Arachidonoyl	   L-­‐α-­‐lysophosphatidic	   acid	   sodium	   salt	   and	  arachidoyl	   L-­‐α-­‐lysophosphatidic	   acid	   sodium	   salt	   were	   purchased	   from	  Echelon	  Bioscience	  (Salt	  Lake	  City,	  UT).	  Dipalmitoyl	  L-­‐α-­‐lysophosphatidic	  acid	  sodium	  salt	  was	   from	  Wako.	  Purified	  human	  sEH,	  Xenopus	   sEH,	   and	  chimera	  (0.6	  µg)	  were	  pre-­‐incubated	  for	  5	  min	  at	  370C	  in	  25	  mM	  Bis	  Tris	  buffer,	  pH	  7.0,	  containing	   1	   mM	   MgCl2	   and	   0.01%	   BSA.	   LPAs	   were	   added	   at	   a	   final	  concentration	   of	   10	   µM	   and	   incubated	   for	   5	   min	   at	   370C.	   The	   reaction	   was	  stopped	   by	   the	   addition	   of	   Biomol	   green	   reagent	   and	   held	   at	   room	  temperature	   for	   60	   min.	   The	   resulting	   green	   color	   was	   measured	   by	   the	  EnVision	  2104	  Multilabel	  Reader	  at	  630	  nm.	  	  
Separation	  and	  quantitation	  of	  EET	  metabolites	  	   The	   epoxide	   hydrolase	   activities	   of	   purified	   recombinant	   Xenopus	   sEH,	  human	  sEH	  and	  chimera	  toward	  10	  µM	  EETs	  (11,12	  EET	  or	  14,15	  EET)	  were	  assayed	   in	   incubation	   mixture	   (final	   volume	   0.5	   ml)	   consisting	   of	   100	   mM	  potassium	   phosphate	   buffer,	   pH	   7.4,	   and	   2	   nmol	   stearic	   acid	   as	   an	   internal	  control.	  The	  reaction	  mixture	  containing	  purified	  recombinant	  protein	  (6.0	  µg)	  was	  incubated	  at	  370C	  for	  5	  min	  and	  the	  reaction	  was	  stopped	  by	  the	  addition	  of	  0.4	  M	  citric	  acid	  and	  I	  mL	  of	  ethyl	  acetate.	  After	  centrifugation	  at	  4000	  rpm	  for	   10	   min,	   the	   upper	   organic	   layer	   was	   transferred	   to	   a	   new	   tube	   and	  evaporated	  under	  nitrogen.	  The	  resulting	  residue	  was	  dissolved	  in	  ethanol	  (20	  µl)	   and	   analyzed	   by	   HPLC	   equipped	   with	   an	   Evaporative	   Light	   Scattering	  Detector	  (ELSD)	  system	  (Prominence-­‐Shimadzu,	  Kyoto,	  Japan)	  using	  a	  TSKgel	  ODS-­‐100Z	  5μm	  column	  (4.4	  mm	  I.D	  x	  15	  cm;	  Tosoh,	  Tokyo,	   Japan).	  To	  detect	  
	   16	  
EET	   metabolites,	   mobile	   phase	   A	   (water:	   acetic	   acid,	   100:0.1),	   and	   mobile	  phase	   B	   (acetonitrile:	   acetic	   acid,	   100:0.1)	  were	   used.	   The	  metabolites	  were	  separated	  at	  a	  flow	  rate	  of	  1	  ml/min,	  with	  a	  linear	  gradient	  of	  A	  to	  B	  from	  50%	  to	  100%	   for	   30	  min.	  DHET	  production	  was	  measured	  by	   a	   calibration	   curve	  prepared	  with	  authentic	  DHETs.	  	  
Sample	  preparation	  and	  analysis	  of	  endogenous	  substrate	  	   Eighty	   milligrams	   of	   Xenopus	   liver	   was	   homogenized	   and	   200	   µl	   of	  methanol	   and	   2	   µl	   of	   formic	   acid	   were	   added.	   The	   homogenates	   were	  centrifuged	  at	  14,000	  rpm	  for	  10	  min	  at	  40C.	  The	  supernatants	  were	  applied	  to	  the	  SPE	  cartridge	  and	  washed	  with	  3	  ml	  of	  water,	  and	  1	  ml	  of	  10%	  methanol.	  The	  sample	  was	  eluted	  in	  0.5	  ml	  acetonitrile	  followed	  by	  1.5	  ml	  ethyl	  acetate.	  These	   fractions	   were	   combined	   and	   dried	   under	   N2	   	  32,33).	   The	   residue	   was	  dissolved	  with	  40	  µl	   of	   ethanol	   for	   analysis	   by	  UPLC/electrospray	   ionization	  (ESI)/MS.	   The	   chromatography	   was	   performed	   with	   a	   C18	   reversed-­‐phase	  column	   (TSK-­‐GEL	   ODS-­‐140HTP,	   4.6	   x	   250	  mm,	   5	   µm)	   and	   the	   UPLC	   system	  (Acquity	  UPLC	  system,	  Waters,	  Milford,	  MA).	  Mobile	  phase	  A	  consisted	  of	  50%	  water,	   30%	   acetonitrile,	   20%	  methanol	   and	   1%	   acetic	   acid.	   Mobile	   phase	   B	  consisted	  of	  80%	  acetonitrile,	  20%	  methanol	  and	  1%	  acetic	  acid.	  A	  flow	  rate	  of	  0.2	  ml/min	  and	  5	  µl	  injection	  volume	  was	  used	  to	  deliver	  the	  mobile	  phases	  A	  and	  B	  with	  a	  linear	  gradient	  from	  40%	  A	  for	  20	  min	  to	  40-­‐100%	  B	  for	  27	  min.	  Mass	   spectrometry	   was	   carried	   out	   using	   a	   Nanofrontier	   LD	   mass	  spectrometer	   (Hitachi,	  Tokyo,	   Japan)	  and	  ESI.	  The	  analytes	  were	  detected	  by	  tandem	  TOF	  monitored	  by	  total	  ion,	  m/z	  319	  (EETs).	  	  
Statistics	  and	  kinetics	  analysis	  
	   The	  kinetic	  parameters	  Km	  and	  Vmax	  were	  obtained	  using	  Prism	  enzyme	  kinetic	   software	   (Graphpad	   Software,	   La	   Jolla,	   CA).	   Statistical	   analysis	   was	  performed	  with	  Student’s	  t-­‐test	  and	  p<0.05	  were	  considered	  significant.	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I.3	  Results	  
Expression	  and	  purification	  of	  Xenopus	  sEH	  and	  its	  catalytic	  activity	  	   I	   found	   two	   substitutions	   of	   amino	   acid	   in	   the	   sequence	   deduced	   from	  our	   Xenopus	   sEH	   cDNA	   compared	   with	   that	   of	   the	   original	   Xenopus	   sEH	  reported	  in	  GenBank.	  I	  prepared	  Xenopus	  sEH	  with	  substitutions	  of	  amino	  acid	  residues	   with	   N29T	   and	   H146R	   (designated	   mutant	   1).	   Both	   amino	   acid	  exchanges	  occurred	  in	  the	  phosphatase	  domain.	  The	  purified	  Xenopus	  sEH	  was	  reacted	   with	   the	   generic	   substrate	   4-­‐Methylumbelliferyl	   Phosphate	   for	  phosphatase	   activity	   and	   with	   PHOME	   as	   a	   substrate	   for	   EH	   activity.	   The	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   To	   investigate	   whether	   mutant	   1	   and	   wild-­‐type	   Xenopus	   sEH	   lack	  phosphatase	   activity,	   a	   homology	   search	   of	   the	   phosphatase	   domain	   was	  performed	   with	   other	   members	   of	   haloacid	   dehalogenase	   (HAD),	  phosphonoacetaldehyde	   hydrolase	   (Phos),	   and	   phosphoserine	   phosphatase	  (PSP).	   Several	   amino	  acid	   residues	  have	   important	   functions	   in	   the	   two-­‐step	  catalytic	  mechanism	   of	   phosphatase	   compared	  with	   HAD,	   Phos	   and	   PSP	   	  34).	  Based	   on	   the	   sequence	   homology	   with	   human	   sEH	   phosphatase	   domain,	  almost	   all	   residues	   important	   for	   phosphatase	   activity	   are	   conserved	   in	  
Xenopus	   sEH,	   but	   the	   amino	   acid	   residue	   of	   the	   11th	   aspartic	   acid	   was	   not	  conserved	  (Fig.	  I-­‐2).	  	  	   This	   amino	   acid	   residue	   is	   thought	   to	   be	   important	   for	   phosphatase	  activity.	  Wild-­‐type	  Xenopus	  sEH	  has	  a	  glycine	  residue	  at	  the	  11th	  position	  and	  sEH	   G11D	   (designated	   mutant	   2)	   was	   constructed	   by	   exchanging	   the	   11th	  glycine	   with	   aspartic	   acid.	   The	   EH	   activity	   of	  Xenopus	   sEH	   G11D	  was	   lower	  than	   that	  of	  human	   sEH,	   and	  Xenopus	   sEH	  G11D	   lacked	  phosphatase	   activity	  (Fig.	  I-­‐1).	  These	  results	  suggest	  that	  other	  amino	  acid	  substitutions	  or	  regions	  of	   the	   peptide	   chain	   are	   required	   for	   phosphatase	   activity.	   The	  Xenopus	   sEH	  chimera	  was	   constructed	  by	   combining	   the	  human	   sEH	  phosphatase	  domain	  and	   Xenopus	   sEH	   epoxide	   hydrolase	   domain.	   The	   N-­‐terminal	   domain	   of	  
Xenopus	   sEH	  (1st	   to	  232th	  amino	  acids)	  was	  exchanged	   for	  human	  sEH	  (1st	   to	  229th	   amino	   acids).	   The	   EH	   activity	   of	   the	   chimera	   was	   measured	   and	   was	  found	   to	   be	   similar	   to	   that	   of	  wild-­‐type	  Xenopus	   sEH.	   The	   chimera	   also	   had	  phosphatase	   activity,	   suggesting	   the	   C-­‐terminal	   domain	   of	  Xenopus	   sEH	  was	  not	  a	  cause	  of	  the	  lack	  of	  phosphatase	  activity	  (Fig.	  I-­‐1B).	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- - - MT LRAAV FD LDGV LAL PAV FGV LGRT EEALAL PRGL LNDAFQKGGPEGAT T RLMKGE I T L SQW I PLMEENCRKCSET
- - MAGKRFV L FD LGGV L LT PGPQSAFQRL ET SLH L PSGF LQNV FT RSGSEGPFAMAERGK I P F SKFVAEMNKECRAFAEE
- - - MARRFAL FD LGGV L FGPGLQH F LGSCERSYAL PRN F LRDV L FAGGSD SPHAKVMRGQ I T L SQL F L EVD EGCRQHAST
MAQNMKKKAV L FD LGGV L F EPPQNALRKYGEQLGL PGSF L EKAM I QGRPDNAFCRMERGESTARQFAEEFT KDCQT L SKE
- - - M I DKKVV L FD LGGV I VT PPQRAL LKYCEEAGL PRN F I FNV I SQGRANNT FARL ERGE I T VTQFAT EF EQECRRVAEA
- - - - MT I KAV I FDMGGV I L PAPMHYWKS I EKTHN LRDGSVV ET I I SKD FY PH FKL F ETGRLT SED LDPL FTH I YN FQNNR
AKVCL PKN F S I KE I FDKA I SARK I NRPMLQAALMLRKKGFT TA I LTNTWLDDRAERDGLAQLMCELKMH FD F L I ESCQVG
SGV SL PESF SL EQAFHGMF ENGG I NKPMLKAAVKLRHHGFKT CV LTNNW I DD SPQRSL SAEV L SSL SRH FD LVV ESCR I G
AG I T L PT T F S I AHV F EEMAAKGT LNAPL LRAASMLRRNGFKT CV FTNNWVDD SMGRL FT SSL LT VVQRH FD L L I ESCRVG
EGQV L PKD FNASSMFDT FMN I KMV PDMLNAV SV LKQNGVKTAAVTNNY I DDREQN SLGAGVMT T L SSFY FDH FV ESCRFG
QSLV I PD SF SAT EMVN - - FKD PD L I PEMLNAVAV LKENGVQT CALTNNY I DNT SNRAYAAGGLTAFT FY FD EFV ESCRLG
VGD I L P I FV EV SSQ I QHT PL L PEMV EL I KSLRLAGYRT I L I TNN FYTD - - - - - - RARL L PT V PSQVGL L FDDV L ESCRLG
MVKPEPQ I YKF L LDT LKASPSEVV F LDD I GAN LKPARD LGMVT I LVQDTDTALKEL EKVTG I QL LNT PA - - - - - - - - P L P
MRKPETQ I Y EYALKL LHAKPKET I F LDD I GAN LKPAREMG I AT V LVKDT ETALKELQAL SNV PL I ENEE- - - - - - - - VAP
LHKPDPR I YT YAL EV LQAQPQEV I F LDD I GEN LKPAREMGMAT I LVRDTDT V LKELQEL SGVQL LQQEE- - - - - - - - P L P
KRKPDQS I FN EALKKLGVKAEEAV F LDD LGPNVKAAREMG I ST V LVKDT SAALKELQEVTG I DV FQ- - E - - - - - - - - AKP
I RKPDPN I FH EALARLGAEASQAV F LDD SEVNT KAAEALG I T S I LVQDPKTAL EQLK I VTG I DV FK- - Q - - - - - - - - AGP
LRKPDT K I Y ELAL ERSKLHPSDCV F LDD LGSN LKSAKEMG I T T I KVV SSQQA I HD LGN I LKLN F SY PPET RDC I PREV L P
T SCNPSDMSHGYVT VKPRVRLH FV ELGSGPAVCLCHGF PESWY SWRYQ I PALAQAGYRV LAMDMKGYGESSAPPE I EEYC
I PANPDKVTHGFVT VKPGVKLHYV EMGNGPV I CLCHGF PESWY SWRFQ I PALADAGFRV I A FDMKGYGD SSAPHE I EEY S
T T CDPATMSHGYV P I RPGVQLH FV EMGHGPA I CLCHGF PESWL SWRYQ I PALADAGFRV I A L EMKGYGESTAPPE I EEY S
V SVHHERV PH SYAT T RSGVKFHYVD I GSGPPV I FCHGF PESWYEWKSQ I PAVAAAGFRV I AMDMKGYGESSNPPE I EEYT
I T VHPD EVTH SYVT T RSKVRFH FT ELGSGPPVV LCHD F EEDWEAWRSLMPELA I AGFRA I A LD LKGFGESSKPTDT EQYT
I EK I N EL I T RRTGTDNKV ET I RKFRHGQSNPT YY I RT VRGSQYV LRKKPSGSL L PKAHQVDREFK I MNALQGLV PL PKT L
MEV LCKEMVT F LDKLGL SQAV F I GHDWGGMLVWYMAL FY PERVRAVASLNT PF I PANPNMSPL ES I KANP - V FDYQLY FQ
QEQ I CKD LV SF LDALG I SQASF I GHDWGGAVVWNMAL FY PERVRAVASLNT PF FT SEPGVNAL ER I KANP - I FDYQLY FQ
QEQ I CKD LT I F LDKLG I PQAV F I GHDWGGAVVWNMAL FY PERVRAVASLNT PYRPADPT VD I V ETMKSF P - MFDYQFY FQ
L ERMCKDMAEFMDT LC I PQAT F I GHDWGGF FVWNYATHY PDRV SAVGG I CT PF F PANDTMNPWEN I NKNPGLYDYQLY FN
LK I LCRDMT EF LDALG I AQVT L I GKGMGSAFAWT FANHT TDRVRAVAG I NT SPSVV I PDT LYGDQ I KR I GSLQDY I KFRH
LYD ET T LDT SFY LMEYQKGR I F LKPSL PELT PPERRRVY EEALKT LAT I H SVDY EKVGLQD FGRTDGYMARN LKRWSD SY
EPGVAEAEL EQN L SRT FKSL FRASD E- - - - - SV L SMHKVCEAGGL FVN SPEEPSL SRMVT E- - - EE I QFYVQQFKKSGFR
EPGVAEAEL EKN L ERT FKV F FRGSSEKDRL PT T LT TMNVRERGG I LVGTD EDT PL SS I I N E - - - AD LHYYVAQFKKSGFR
EPGVAEAEL EKD I GRT LKAL I RST RPEDRLH SV PGL LGVQERGGL LVGF PED I PESL I LHG- - - AELQYY I ERFQRSGFR
EVGPPEAE I EANV EKFVKAFMRRPL ELKE I GF SVAGVRAK- - - GG I MAG I PDD I N ST L LT E - - - DDVQYYVKQFKT CGLR
CDRNNNNNPD I EMEQFYR I AT CH SSDTNPT KHDRCLQG I DVKD F EL ST KASMNCLC I EADKRGKKQLGGHHRST KSKSKS
QMAKT EE I QEM I KL EAY LKAN L PKSGKST I VHGD FRVDN L I I EENE I KVKGV LDWEL ST I GD PL SD LAT F L FVYYV PNRM
GPLNWYRNMERNWKWACKSLGRK I L I PA LMVTAEKD FV LV PQMSQHMEDW I PH LKRGH I EDCGHWTQMDKPT EVNQ I L I K
GPLNWYRNMQRNSEWS I SAHGWK I LV PALMVTAGKD FV L L P I MT KGMEN L I PN L SRGH I EECSHWTQMERPAAVNE I L I K
GPLNWYRNMRPNWRWAL SAKDRK I LMPALMVTAGKDVV L L PSMSKGMEEW I PQLRRGH L EACGHWTQMERPAALNR I LV E
SMLNWYRTMEVNWKFNHRA I GRKLYMPALMVT CAWDEV L PPSV SKFMDPFVVN LT RAH I ED SGHWASL EQPKKLNK I LVD
RGANWFRNNAANWEWNRRLNGRML L I PALVVT SGQGSPKDV PDV SELKKW I PEV EH SHV SGCE I KTDRERSSELNR I LRK
I L L PGLGDY SESD LHRMG I PT I KECL ELYAKYTNT EVVDPELWT YYMAFV I FRFAS I I QGVYKRSQLKNASST EASQLGP
WLD SDARNPPVV SKM- - -
WLGEV LN L PVT SKL - - - -
WL EGL PPDGAMLRV SRL -
WLNKVHKD SNRP I F PSSL
WL FT I YAGEHT PLMPM- -
LVRKLAAEGM- - - - - - - -
1
- - - MT LRAAV FD LDGV L L P V FGV LGRT EE A PRGL LND FQKGGPEGAT T RLMKGE I T L SQW I PLMEENCRK SET
- - MAGKRFV L FD LGGV L LT PGPQSAFQR ET SLH PSGF LQNV FT RSGSEGPFAMAERGK I P F KFVAEMNKECRAFAEE
- - - MARRFAL FD LGGV L FGPGLQH F LGSCERSYA P F LRDV L AGGSD SPHAKVMRGQ I T SQL F L EV EGCRQHAST
MA NMK KAV L FD LGGV L F EPPQNALRKYGEQLGL PGSF L EK M I QGRP NAFCRMERGESTARQFAEE T KDCQT L SKE
- - - M I DKKVV L FD LGGV I VT P QRAL LKYCEE G PR F I FNV I SQGRANNT FARL ERGE I T V Q AT E EQECRRVAEA
- - - - MT I KAV I FDMGGV I L PA MHYWKS I EKTHN LRDGSVV ET I I SK FY PH FKL F ETGRLT SED LDP TH I YN FQNNR
AKVCL KN F S I KE I FD I SARK I NRPMLQ A MLRKKGFT TA I TNTWLDDRA RDGLAQLMCELKMH FD F L I ESCQVG
SGV SL PESF SL EQAFHGMF ENGG I NKPMLK AV LRHHGFKT C TNNW I DD SPQRSL SAE L SSL SRH FD LVV ESCR I G
AG I T L T T F S I HV F EEMAAKGT LNAPL LRAASMLR NGFKT CV FTNNWVDD SMGRL FT SL LT VV RH FD L L I ESCRVG
EGQV L PKD ASSMFDT FMN I KM PDMLNAV S LKQNGVKTAA TNNY I DDREQN SLGAGVMT T L SSFY FDH FV ESCRFG
QSLV I D S SAT EMVN - - FKD PD L I PEMLNAVAV LK NGVQ CA TNNY I DNT SNRAYAA GLTAFT FY FD EFV ESCRLG
VGD I L P I FV V SSQ I QHT PL L PEMV EL I KSLR AGYRT I L I NN FYTD - - - - - - RARL L PT V PSQVGL L FD V L ESCR G
MVKPEPQ I YKF L LDT LKASPSEV F DD I G N LKPARD LGMVT I LVQDTDTALKEL EK TG I QL LNT PA - - - - - - - - P L P
MRKPETQ I Y EYALKL LHAKPKET I F LDD I GAN LKPAREMG I AT V LVKDT ETALKELQAL SNV PL I ENEE- - - - - - - - VAP
LHKPDPR I YT YAL EV LQAQPQEV I F LDD I GEN LKPAREMGMAT I LVRDTDT V LKELQEL SGVQL LQQE - - - - - - - - P L P
KRKPDQS I FN EALKKLGVKAEEA F LDD LG NVKAAREMG I ST V LVKDT S ALKELQE TG I V FQ- - - - - - - - - - AKP
I RKPDPN I F EALARLGAEASQAV F DD SEVNT KAAEALG I T S I LVQDPKTAL EQLK I VTG I V FK- - Q - - - - - - - - AGP
LR PDT K I Y ELAL ERS LHPSDCV F LDD LGSN LKSAKEM I T T I KVV SSQQA I HD LGN I LKLN SY PPET RDC I REV L P
T SCNPSD SHGYVT VKPRVRLH FV ELGS PA CLCHG PESWY SWRYQ I PALAQAGYRV LAMDMKGYGESSAPPE I EEYC
I PANPDKVTHGFVT VKPGVKLHYV EMGN P I CLCHG PESWY SWRFQ I PALADAGFRV I A FDMKGYGD SSAPHE I EEY S
T T CDPATMSHGYV P I RPGVQLH FV EMGH PA I CLCHG PESWL SWRYQ I PALADAGFRV I A L EMKGYGESTAPPE I EEY S
V SVHHERV PH SYA T RSGVKFHYVD I GS PP I FCHGF PESWYEWKSQ I PAVAAAGFRV I AMDMKGYGESSNPPE I EEYT
I T VHPD EV H SYVT T RSKVRFH FT ELGSGPPVV LCHD F EE WEAWRSLMPELA I AGFRA I A LD LKGFGES KPTDT EQYT
I EK I N E I RRTGTDNKV ET I RKFRHGQSNPT YY I T RGSQYV LRKKPSGSL L P AHQV REFK I MNALQG V PL PKT L
MEV LCKEMVT F LDKLGL SQAV F I GHDWGGMLVWYMAL FY P RVRAVASLNT PF I PANPNMSPL ES I KANP - V FDYQLY Q
QEQ I CKD LV SF LDALG I SQASF I GHDWGGAVVWNMAL FY P VRAVASLNT PF FT EPGVNAL ER I KANP - I FDYQLY Q
QEQ I CKD LT I F LDKLG I PQAV F I GHDWGGAVVWNMA FY P VRAVASLNT PYRPADPT VD I V ETMKSF P - MFDYQFY Q
L ERMCKDMA FMDT LC I PQAT F I GHDWGGF FVWNYATHY PDRV SAVGG I CT PF F PANDTMNPWEN I NKNPGLYDYQLY FN
LK I LCRDMT EF LDALG I AQV L I GKGMGSAFAWT FANHT TDRVRAVAG I NT SPSVV I PDT LY DQ I KR I GSLQDY I FRH
LYD E T LDT SFY LM YQKGR I F L PSL PELT PPER RVY EEALKT LAT I H S DY EKVGLQD FGRT GYMARN LKRWSD SY
E GVAEAEL Q L SRT F F ASD E- - - - - SV L SMHKVCEAGGL FVN SPEEPSL SRMVT E- - - EE I QFYVQQFKKSGFR
E GVAEAEL EK L RT FKV F FRGSSEKDRL P T LT TMNVRERGG I LVGTD EDT PL SS I I N - - - AD LHYYV QFKKSGFR
E GVAEAEL EKD I GRT K L I ST RPEDRLH SV PGL LGVQERGGL LVGF PED I PESL I HG- - - AELQYY I ERFQ SGFR
EVGPPEAE I A V EKFVK FM RPL ELKE I GF SVAGVRAK- - - GG I AG I PDD I N ST L LT E - - - DDVQYYV QFKT CGLR
CDR NNN PD I EM QFY I AT CH SSDTNPT KHDRCLQG I K F EL ST ASMNCLC I EADKRGK QLGGHHRST KSKSKS
QMAKT EE I QEM I K EAY LKAN L PKSGKST I VHGD FR DN L I I EENE I KVKGV LDWEL ST I GD PL D AT F L FVYYV PNRM
GPLNWY MERNW WACKSLGRK I L I PA LMVTAEKD FV LV PQMSQHMEDW I PH LKRGH I EDCGHWTQMDKPT EVNQ I L I K
GPLNWYRNMQRNSEWS I SAHGWK I LV PALMVTAGKD FV L L P I MT KGMEN L I PN L SRGH I EECSHWTQMERPAAVNE I L I K
GPLNWYRNMRPNWRWA SAKDRK I LMPALMVTAGKDVV L L PSMSKGMEEW I PQLRRGH L EACGHWTQMERPAALNR I LV E
SMLNWYRTMEVNWKFNHRA I GRKLYMPALMVT CAWDEV L PPSV SKFMDPFVVN LT RAH I ED SGHWASL EQPKKLNK I LVD
RGANWFRNNAANWEWNRRLNGRML L I PALVVT SGQGSPKDV PDV SELKKW I PEV EH SHV SGCE I KTDRERSSELNR I LRK
I L L PGLGDY SESD LHRMG I PT I KECL ELYAKYTNT EVVDPELWT YYMAFV I FRFAS I I QGVYKRSQLKNASST EASQLGP
WLD SDARNPPVV SKM- - -
WLGEV LN L PVT SKL - - - -
WL EGL PPDGAMLRV SRL -
WLNKVHKD SNRP I F PSSL
WL FT I YAGEHT PLMPM- -
LVRKLAAEGM- - - - - - - -
1
- - - MT LRAAV FD LDGV LAL PAV FGV LGRT EEALAL PRGL LNDAFQKGGPEGAT T RLMKGE I T L SQW I PLMEENCRKCSET
- - MAGKRFV L FD LGGV L LT PGPQSAFQRL ET SLH L PSGF LQNV FT RSGSEGPFAMAERGK I P F SKFVAEMNKECRAFAEE
- - - MARRFAL FD LGGV L FGPGLQH F LGSCERSYAL PRN F LRDV L FAGGSD SPHAKVMRGQ I T L SQL F L EVD EGCRQHAST
MAQNMKKKAV L FD LGGV L F EPPQNALRKYGEQLGL PGSF L EKAM I QGRPDNAFCRMERGESTARQFAEEFT KDCQT L SKE
- - - M I DKKVV L FD LGGV I VT PPQRAL LKYCEEAGL PRN F I FNV I SQGRANNT FARL ERGE I T VTQFAT EF EQECRRVAEA
- - - - MT I KAV I FDMGGV I L PAPMHYWKS I EKTHN LRDGSVV ET I I SKD FY PH FKL F ETGRLT SED LDPL FTH I YN FQNNR
AKVCL PKN F S I KE I FDK I S RK I NRPMLQA M RKKGFT T I LTNTWLDDRAERDGLAQLMCELKMH FD F L I ES QVG
SGV SL PESF SL EQAFHGMF ENGG I NKPM KAAVK RHHGFKT CV LTNNW I DD SPQRSL SAEV L SL SRH FD LVV ESCR I G
AG I T L PT T F S I AHV F EEMAAKGT LNAPL LRAASM R GFKT CV TNNWVDD SMGRL FT SSL T VVQRH F L L I ESCRVG
EG V L P D FNASSMFDT FMN I KMV PDMLNAV SV LKQNGVKTA VTNNY I DREQN SLGAGVMT T L SSFY DH FV ESCRFG
QSLV PD SF SAT EMVN - - FKD D L I PEMLNAV V KE GVQT CALTNNY I DNT SNRAYAAGGL A T FY D EFV ESCRLG
VGD I L P FV EV SSQ I QHT PL L EMV EL I KSLRLAGYRT I L I TNN FYT - - - - - - RARL L PT V PSQVGL DDV L ESCRLG
MVKPE Q I YK L T L S SEVV F DD I G N KPA D GMVT VQDTDT LK E VTG I QL LNT A - - - - - - - - P L P
MRKPETQ I Y EYA KL LHAK KET F LDD I G N PAREMG I AT VKDT TALKELQAL SN PL I ENE - - - - - - - - VAP
LHKPD I YT Y EV LQAQ QEV I DD I GEN LKPA EMGMAT I LVRDT T V LKELQEL GVQL LQ E - - - - - - - - P L P
KRKPDQS I EALKKLGVKAEEA F DD L PN KAAREMG I ST LVKDT SA LKELQEVTG I DV FQ- - - - - - - - - - A P
I RKPD N I H EALARLGAEASQAV F DD SEVNT KAA ALG I S I VQDPKTAL EQ K I VT I DV FK- - Q - - - - - - - - GP
LRKPD K I Y LAL ERSKLH SDCV F LDD LGSN KSAKEMG I KVV SSQQA I HD LGN I LKLN F SY P ET R C I PREV P
T SCNPSDMSHGYVT VKPRVRLH F E GSGP VCLCHGF PESWY SWRYQ I PALAQAGYR LAMDMKGYGESSAPP I EEYC
I PANPDKVTHGFVT VKPGVKLHYV EMGNGPV I CLCHGF PESWY SWRFQ I PALADAGFRV I A FDMKGYGD SSAPH I EEY S
T T CDPA MSHGYV P I RPGVQLH FV EMGHGP I CLCHGF PESWL SWRYQ I PALADAGFRV I A EMKGYG STAPP I EEY S
V SVHHERV PH SYAT T RSGVKFHY D I GSGP V I FCHGF PESWYEWKSQ I P VAAAGFR I A MKGYG SSNPP I EEYT
T VHPD EVT SYVT T RSKVRFH FT E GSGPP V LCHD F EEDWE WRSLMPELA I AGFR I A L LKGFGESSKPTDT EQYT
I E I N EL T RRTGTDN V ET I RKFRHGQSNPT YY I RT VR SQYV LRKKPSGSL L PKAHQVDRE K I MNALQGLV L PKT L
EV LCKE VT DKLGL SQAV F I GHDWG ML WYM L Y PERVRA ASLN PF I PANPNMSPL ES I KANP - V FDYQLY FQ
QEQ I CKD LV SF LDA G I SQASF I GHDWG A VWNM L YPERVRA ASLN PF FT SEPGV AL ER I KANP - I FDYQLY FQ
QEQ I CKD LT I F LDKLG I P AV F I GHDWG AVVWNM L YPERVRA ASLN PYRPADPT VD I V ETMKSF P - MFDYQFY FQ
L ERMCKDMAEFMD LC I PQ T F I GHDWG F F WNY THY PDRV SA GG CT PF F PANDTMNPWEN I NKNPGLYDYQLY FN
LK I LCRDM EF LD LG I QVT L I GKGMG AFAWT F NHT T RVRA AG I N SPSVV I PD LYGDQ I KR I G LQDY I KFRH
YD ET D SFY MEYQKGR F LKPSL PELT PPER R Y EEALKT LAT I H SVDY E VGLQ FGRTDGYMA N KRWSD SY
EPGVAEAEL EQN L SRT FKSL FRASD E- - - - - SV SMHKVC AGGL FVN S EEPSL SRM T E- - - EE I QFYVQQFKKSG R
E GVAEAEL EKN L ERT FK F FRGSSEKDRL PT T T TMNVR GG I LVGTD EDT PL S I I N E - - - AD LHYYV QFKKSG R
EPGVAEAEL EKD I GRT LKAL I RST RPEDRLH SV PGL GVQ GGL LVGF ED I PESL I LHG- - - AELQYY I ERFQRSG R
EVGPP AE I ANV EKFVKAFMRRPL ELKE I GF SVAGVRAK- - - GG I MAG I PDD I N ST L LT E - - - DDVQYYVKQFKT CGLR
CDRNNNNNPD I EMEQFYR I A CH SSDTNPT KHDR LQG I DVKD F EL T KASMNCLC E DKR K QL GHHRS KS SKS
QMAK E I QEM I KL AY LKAN L P SGKST I VHGD F VDN L I I EENE I VK DWEL ST I GD PL S LAT F L FVYYV NRM
G LNWYRNM R W WAC G K I L I PA L VTAEKD FV LV PQMSQHMEDW I H LKRGH I EDCGHWTQMDKPT EVN I L I K
G LNWYRNMQR S WS I AHGWK I LV PALM AGKD FV L L P I MT KGMEN L I N L SRGH E CSHWTQMERP AVNE I L I K
G LNWYRNMRPNWRWA S KD K I LMPALM TAGKDVV L L PSMSKGMEEW I QLRRGH EACGHWTQMERPAALN I LV E
SMLNWYRTM V WKFNHR I G KLYMPALMVT CAWDEV L PS KF DPFVVN LT RAH I ED SGHWASL EQP KLNK I LVD
RGA WFR NAANW WNR LNGRML L I PALVVT SGQGSPK P V SELK W I PEV EH SHV SGCE I TD ER SELNR I L K
I L L PGLG Y ESD HRMG I PT I KECL ELYAKYTNT E DP LWT YYMAFV I FRFAS I I QGVYK Q KN SST EASQLGP
WLD SDA PPVV S M- - -
WL EV LN L PVT SKL - - - -
WL EGL PPDGAMLRV SR -
WLNKVHKD SNRP I F PSSL
WL FT I YAGEHT PLMPM- -
LVR LAAEGM- - - - - - - -
1
	  
Fig.	   I-­‐2	   Sequence	   alignment	   between	   Xenopus	   sEH	   and	   sEH	   derived	   from	   other	  species.	   Black	   boxes	   indicate	   the	   active	   sites	   of	   phosphatase	   activity.	   The	   arrow	  indicates	   a	   different	   amino	   acid	   of	   phosphatase	   active	   site	   between	   human	   and	  
Xenopus	  sEH.	  Thr27	  or	  Arg146	  indicated	  by	  open	  circle	  was	  substituted	  by	  Asn	  or	  His,	  respectively,	  in	  the	  isolated	  Xenopus	  sEH.	  	   	  	  
Xenopus	  sEH	  activity	  toward	  endogenous	  substrates	  	   To	   investigate	   the	   EH	   activity	   of	   Xenopus	   sEH	   toward	   the	   endogenous	  substrates,	  11,12-­‐EET	  and	  14,15-­‐EET,	   the	  metabolized	  DHETs	  were	  analyzed	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Epoxide	  hydrolase	  and	  phosphatase	  assay	  in	  various	  conditions	  	   Ionic	   strength	   and	   pH	   of	   buffer,	   and	   reaction	   temperature	   were	  assessed	   to	   determine	   the	   optimal	   condition	   for	   both	   EH	   and	   phosphatase	  activity.	  	  
























































































































































Fig.	   I-­‐4	   The	   effect	   of	   ionic	   strength	   and	   pH	   of	   buffer,	   and	   reaction	   temperature	   on	  catalytic	   activities	   of	   Xenopus	   and	   human	   sEH.	   (A)	   Purified	   Xenopus	   sEH	   or	   human	  sEH	  (0.5	  µg)	  was	  incubated	  with	  25	  µM	  PHOME	  with	  10,	  25,	  50,	  or	  100	  mM	  Bis	  Tris	  buffer	  pH	  7.0	  at	  300C.	  (B)	  EH	  activities	  toward	  25	  µM	  PHOME	  in	  25	  mM	  Bis	  Tris	  buffer,	  pH	  5.5,	  6.0,	  6.5,	  7.0,	  or	  7.5	  at	  300C	  (C)	  EH	  activity	  in	  25	  mM	  Bis	  Tris	  buffer	  pH	  7.0	  at	  20,	  25,	   30,	   or	   370C.	   (D-­‐F)	   Purified	   sEH	   (5	   µg)	   were	   each	   incubated	   with	   0.5	   mM	   4-­‐Methylumbelliferyl	  Phosphate	  in	  the	  various	  conditions	  descrived	  above.	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  The	  pH	  and	   ionic	   strength	  of	  buffer	  was	  evaluated	  with	  10-­‐100	  mM	  Bis	  Tris	  buffer,	  pH	  5.5-­‐7.5,	  at	  the	  different	  temperature	  from	  20	  to	  370C.	  Xenopus	  sEH	  revealed	  maximal	  EH	  activity	  in	  10	  mM	  	  Bis	  Tris	  buffer,	  pH	  7-­‐7.5,	  at	  300C,	  while	  human	  sEH	  showed	  maximal	  EH	  activity	  in	  10	  mM	  Bis	  Tris	  buffer,	  pH	  7-­‐7.5,	  at	  370C	   (Figs.	   I-­‐4A;	   B;	   C).	   In	   the	   phosphatase	   activity	   of	   human	   sEH,	   maximal	  activity	  was	  obtained	  in	  25	  mM	  Bis	  Tris	  buffer,	  pH	  6.0,	  at	  370C	  (Figs.	  I-­‐4D;	  E;	  F).	  However,	   Xenopus	   sEH	   did	   not	   show	   phosphatase	   activity	   under	   these	  conditions.	  	   The	  EH	  activity	  of	  Xenopus	  and	  human	  sEH	  were	  assessed	  in	  the	  presence	  of	   a	   selective	  EH	   inhibitor,	  N,	  N’	  Dicyclohexylurea	   (DCU)	   	  35).	   DCU	  efficiently	  inhibited	  the	  EH	  activities	  of	  Xenopus	  and	  human	  sEH	  at	  a	  concentration	  of	  50	  nM	   (Fig.	   I-­‐5A).	   The	   EH	   activities	   of	   Xenopus	  and	   human	   sEH	   were	   detected	  using	   PHOME,	   and	   Km	   and	   Vmax	   were	   determined.	   The	   Xenopus	   sEH	   had	  higher	  Km	   (19.16±7.64	   µM)	   and	   lower	  Vmax	   (147.08±30.2	   nmol.min-­‐1.mg-­‐1)	  than	   that	   of	   human	   sEH,	   with	   Km	   (17.27±5.31)	   and	   Vmax	   (227.42±36.6	  nmol.min-­‐1.mg-­‐1)	  (Figs.	  I-­‐5B;	  C).	  	  


























































Kinetic parameter Human Xenopus 
Km (µ  M)  17.27 ± 5.31  19.16 ± 7.64
 Vmax (nmol/min/mg)  227.42 ± 36.3  147.08 ± 30.2! 	  
Fig.	  I-­‐5	  Inhibition	  of	  EH	  activity	  by	  DCU	  and	  kinetic	  analysis	  of	  EH	  activity.	  	  (A)	  Purified	  Xenopus	  sEH	  or	  hsEH	  (0.5	  µg)	  was	  incubated	  with	  25	  µM	  PHOME	  	  in	  the	  presence	  of	   0.0-­‐0.2	  µM	  DCU.	   (B,	   C)	   Lineweaver-­‐Burk	  plots	   of	   the	   epoxide	  hydrolase	  activities	   toward	  PHOME	  and	  the	  kinetic	  parameters	  were	  obtained	  using	  Graphpad	  Prism	  enzyme	  kinetic	  software.	  Results	  are	  expressed	  as	  the	  means	  ±	  SD	  of	  triplicate	  experiments.	  	  	  	  
Presence	  of	  EETs	  in	  Xenopus	  liver	  	   EETs	  production	  in	  the	  Xenopus	  liver	  as	  an	  endogenous	  substrate	  of	  sEH	  was	  characterized	  (Fig.	  I-­‐6).	  The	  endogenous	  EETs	  were	  measured	  by	  LC-­‐MS.	  Peaks	   of	   11,12-­‐EET,	   14,15-­‐EET	  were	   detected,	   and	   the	   addition	   of	   authentic	  11,12-­‐EET,	   14,15-­‐EET	   increased	   the	   peak	   height,	   suggesting	   that	   11,12-­‐EET	  and	  14,15-­‐EET	  were	  present	  in	  the	  Xenopus	  liver.
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Fig.	  I-­‐6	  Detection	  of	  11,12-­‐EET	  and	  14,15-­‐EET	  in	  Xenopus	  liver	  by	  LC-­‐MS.	  	  
Xenopus	   liver	   (80	   mg)	   were	   homogenized	   and	   analyzed	   by	   UPLC/ESI/MS.	   (A)	   The	  total	   ion	   chromatogram	  of	  Xenopus	   liver	   (B,	   C)	   the	   selected	   ion	   chromatogram	  with	  
m/z	   319	   (EETs).	   (D)	   Selected	   ion	   chromatogram	  with	  m/z	   319	   of	   Xenopus	   liver	   by	  addition	   of	   authentic	   11,12-­‐EET	   and	   14,15-­‐EET	   (0.4	   pmol).	   TIC,	   total	   ion	  chromatogram;	  XIC,	  extracted	  ion	  chromatogram.	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RNA	  and	  protein	  levels	  of	  Xenopus	  sEH	  during	  embryonic	  development	  	  






































Fig.	  I-­‐7	  The	  mRNA	  and	  protein	  levels	  of	  Xenopus	  sEH	  in	  embryos.	  (A)	  Xenopus	  sEH	  mRNA	  levels	  were	  detected	  at	  the	  stages	  0,	  10.5,	  18,	  23,	  26,	  30,	  and	  38	   of	   Xenopus	   embryo.	   Total	   RNA	   was	   isolated	   from	   embryos	   and	   RT-­‐PCR	   was	  performed.	   Amplified	   DNA	   fragments	   were	   analyzed	   by	   electrophoresis	   with	   2%	  agarose	  gel.	  The	   ratio	  of	  Xenopus	  sEH	  mRNA/histone-­‐H4	   in	   the	   stage	  0	  was	   set	   at	  1.	  The	   values	   on	   the	   graphs	   are	   the	   means	   ±	   SD	   of	   three	   separate	   samples.	   Band	  intensity	  was	  measured	  by	  NIH	  image	  and	  normalized	  to	  that	  of	  histone-­‐H4.	  (B)	  xsEH	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protein	   levels	   in	  Xenopus	  embryos	  were	  detected	  by	  Western	  blotting.	  Ten	  embryos	  were	   homogenized	   and	   separated	   into	   three	   distinct	   layers:	   lipid,	   cytoplasmic,	   and	  pigment	   granule/yolk.	   The	   cytoplasmic	   layer	   (30µg	   protein)	  was	   subjected	   to	   SDS-­‐polyacrylamide	   gel	   electrophoresis	   and	   analyzed	   by	   western	   blotting	   with	   the	  antibody	  against	  human	  sEH	  or	  β-­‐actin.	  Xenopus	  sEH	  protein	  levels	  were	  normalized	  by	  expression	  level	  of	  β-­‐actin	  protein.	  The	  ratio	  of	  Xenopus	  sEH	  protein/	  β-­‐actin	  in	  the	  stage	  0	  was	  set	  at	  1.	  The	  values	  on	  the	  graphs	  are	  the	  means	  ±	  SD	  of	  three	  separate	  samples.	  	  
	  
Expression	   of	   Xenopus	   sEH	   in	   various	   tissues	   and	   localization	   of	   sEH	  
mRNA	  in	  the	  embryo	  by	  WISH	  	   To	   investigate	   the	   distribution	   of	   Xenopus	   sEH	   in	   various	   tissues,	   total	  RNAs	   were	   extracted	   from	   adult	   Xenopus.	   RT-­‐PCR	   was	   then	   performed	   on	  brain,	  heart,	  liver,	  lung,	  kidney,	  eye,	  pancreas	  and	  spleen	  (Fig.	  I-­‐8).	  The	  highest	  expression	  was	  detected	  in	  the	  liver,	  with	  the	  lowest	  expression	  in	  the	  brain.	  The	  localization	  of	  Xenopus	  sEH	  mRNA	  in	  embryos	  was	  investigated	  by	  WISH	  at	   stage	  30,	   the	  middle	   tailbud	   stage	   (Fig.	   I-­‐9).	   The	   accumulation	   of	  Xenopus	  
sEH	  mRNA	  was	  detected	  almost	  totally	  in	  the	  head	  region.	  The	  localization	  of	  





















Fig.	  I-­‐8	  	  sEH	  mRNA	  distribution	  in	  several	  tissues	  of	  Xenopus	  laevis.	  Total	  RNA	  was	   isolated	   from	   the	  brain,	  heart,	   liver,	   lung,	   kidney,	   eye,	  pancreas,	   and	  spleen	  and	  converted	  to	  cDNA.	  The	  amplified	  DNA	  fragments	  were	  run	  on	  an	  agarose	  gel	   (1%)	   and	   visualized	  with	   ethidium	  bromide	   staining.	   The	   band	   intensity	   of	   sEH	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was	   quantified	   using	   NIH	   Image	   and	   normalized	   by	   histone-­‐H4.	   The	   values	   on	   the	  graphs	  are	  the	  means	  ±	  SD	  of	  three	  separate	  samples.	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I.4	  Discussion	  	   I	   isolated	   Xenopus	   sEH	   cDNA	   in	   this	   study.	   The	   sequence	   homology	   of	  
Xenopus	   sEH	   compared	   with	   human	   sEH	   was	   high	   in	   the	   C-­‐terminal	   region	  (65%).	   The	   amino	   acid	   residues	   forming	   the	   catalytic	   triad	   of	   the	   EHs	  were	  first	   identified	   from	   sequence	   alignment	   with	   the	   sequence	   of	   haloalkane	  dehalogenase	   	  25,36).	   The	   role	   of	   this	   residue	   is	   nucleophilic	   attack	   to	   the	  epoxide	  ring	  	  37).	  The	  catalytic	  triad	  of	  rat	  sEH	  is	  composed	  of	  three	  active	  sites	  residues:	  Asp333,	  Asp495	  and	  His523	  	  38).	  In	  human	  sEH,	  the	  catalytic	  triad	  is	  represented	   by	   Asp335,	   Asp496,	   and	   His524	   (triangles	   on	   Fig.	   I-­‐2).	   These	  residues	   also	   aligned	   in	   the	  Xenopus	   sEH,	   spaced	   over	   Asp336,	   Asp503,	   and	  His531.	   Two	   tyrosines	   (Tyr382	   and	   Tyr465)	   polarized	   the	   epoxide	   in	   the	  human	  enzyme	  (circles	  on	  Fig.	  I-­‐2)	   	  39).	  These	  residues	  and	  their	  approximate	  spacing	  are	  also	  conserved	  in	  the	  Xenopus	  sEH	  enzyme	  as	  Tyr385	  and	  Tyr472,	  respectively.	  	  	   Most	  amino	  acid	  residues	  were	  important	  for	  the	  phosphatase	  activity	  of	  human	  sEH	  (squares	  in	  Fig.	  I-­‐2)	  were	  conserved	  in	  Xenopus	  sEH.	  Aspartic	  acid	  at	   the	   11th	   position	   (arrow	   in	   Fig.	   I-­‐2)	   is	   believed	   to	   be	   involved	   in	   the	  coordination	   of	   the	   Mg2+	   atom	   in	   the	   active	   site	   while	   participating	   in	   a	  hydrogen	   bond	   with	   arginine	   at	   the	   99th	   position	   	  22).	   This	   aspartic	   acid	   is	  missing	   in	   the	   Xenopus	   sEH	   as	   well	   as	   in	   chicken	   and	   purple	   sea	   urchin	  homolog	  (Xenopus	   laevis,	  GenBank	  accession	  no.	  NM_001093674).	   I	  prepared	  
Xenopus	  sEH	  mutant	  2	  (G11D)	  with	  a	  single	  amino	  acid	  substitution	  at	  Gly11	  (G11D),	  which	  seems	  to	  be	  important	  for	  phosphatase	  activity.	  Unexpectedly,	  
Xenopus	   sEH	  G11D	  did	  not	  show	  phosphatase	  activity.	  However,	   the	  chimera	  consisting	  of	   the	  human	  N-­‐terminal	  phosphatase	  domain	  and	   the	  Xenopus	   C-­‐terminal	   EH	   domain	   displayed	   activity	   when	   assayed	   with	   4-­‐Methylumbelliferyl	  Phosphate.	  This	  result	  showed	  that	  the	  Xenopus	  C-­‐terminal	  EH	  domain	  did	  not	  affect	  the	  N-­‐terminal	  phosphatase	  domain.	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   The	  mammalian	  sEH	  catalyzes	  the	  hydrolysis	  of	  aliphatic	  epoxides	  such	  as	  EETs	  to	  their	  corresponding	  diols,	  DHETs.	  Recently,	  Zebrafish	  	  3),	  chicken	  	  7),	  and	  purple	   sea	  urchin	   	  40)	   have	  been	   found	   to	  produce	  DHET.	  These	   findings	  raise	  the	  question	  of	  whether	  there	  is	  a	  sEH	  homolog	  in	  Xenopus	  with	  epoxide	  hydrolase	  activity	  similar	  to	  those	  of	  the	  mammalian	  enzymes.	  The	  discovery	  of	   a	   sEH	   homolog	   would	   have	   implications	   for	   developmental	   studies.	   In	  mammals,	   sEH	   is	  expressed	   in	  almost	  every	  organs,	   including	   the	   liver,	   lung,	  kidney,	   heart,	   brain,	   and	  ovary	   	  5).	   The	   enzyme	   is	  mainly	   localized	   in	   the	   cell	  cytosol,	  but	  sEH	  in	  some	  cell	  types	  shows	  dual	  localization,	  both	  cytosolic	  and	  peroxisome.	  From	  the	  results	  of	  this	  study,	  we	  conclude	  that	  Xenopus	  sEH	  was	  distributed	   in	   several	   tissues	   and	   organs	   widely	   although	   their	   levels	   of	  protein	  were	  differed.	  The	  characterization	  and	  distribution	  of	  sEH	  in	  Xenopus	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II.1	  Introduction	  
 Lysophosphatidic	  acids	  (LPAs)	  are	  phospholipids	  that	  act	  as	  important	  signaling	  molecules	  	  41)	  and	  have	  been	  shown	  to	  function	  as	  substrates	  for	  the	  N-­‐terminal	   domain	   of	   the	   human	   soluble	   epoxide	   hydrolase	   (sEH)	  4,42).	   LPA	  signaling	   contributes	   to	   a	   range	   of	   diseases,	   including	   neuropathic	   pain	   	  43),	  cardiovascular	   diseases	   	  17),	   cancer	   	  44),	   fibrosis	   	  45),	   infertility	   	  46),	   and	  obesity	   	  47).	   The	   involvement	   of	   LPAs	   in	   signaling	   processes	   such	   as	  inflammatory	   response	   	  48)	   and	   cell	   proliferation	   	  49)	   suggests	   that	   these	  molecules	  would	  be	  good	  drug	  targets	  for	  the	  treatment	  of	  human	  diseases.	  	   sEH	  is	  an	  enzyme	  with	  multiple	  biological	  functions	  and	  is	  involved	  in	  the	  metabolism	   of	   xenobiotics.	   The	   C-­‐terminal	   domain	   of	   sEH	   catalyzes	   the	  hydrolysis	  of	  epoxides	  to	  their	  corresponding	  diols.	  Epoxides	  can	  be	  generated	  via	  oxidation	  of	  olefin	  or	  aromatic	  hydrocarbon	  by	  cytochrome	  P450s.	  sEH	  is	  present	  in	  the	  cytosolic	  and	  peroxisome	  fractions	  of	  the	  cell	  	  50)	  and	  has	  a	  broad	  distribution	   in	   human	   tissues	  51)	   The	   endogenous	   substrates	   of	   sEH	   are	  epoxyeicosatrienoic	   acids	   (EETs).	   EETs	   play	   roles	   in	   the	   anti-­‐inflammatory	  properties	   of	   endothelial	   cells	   	  52),	   vasodilation	   	  53),	   and	   cell	   proliferation	   	  54)	  and	  sEH	  plays	  an	  important	  role	  in	  their	  proper	  functioning.	  	   A	   single	   nucleotide	   polymorphism	   (SNP)	   variants	   of	   sEH	   have	   been	  identified,	   and	   several	   allelic	   variants	   of	   sEH	   have	   been	   shown	   to	   exhibit	  different	   epoxide	  hydrolase	   activities	   	  9,10).	   In	  human	   sEH,	   six	   allelic	   variants,	  K55R,	   R103C,	   C154Y,	   R287Q,	   V422A,	   and	   E470G,	   were	   identified.	  9)	   With	  respect	  to	  phosphatase	  activity,	  Morisseau	  et	  al.	  showed	  that	  the	  sEH	  variant	  R287Q	   exhibited	   lower	   activity	   toward	   myristoyl-­‐LPA	   than	   the	   wild-­‐type	  (WT)	   	  55).	   However,	   the	   effect	   of	   allelic	   variants	   of	   human	   sEH	   on	   the	  phosphatase	   activities	   toward	   other	   LPAs	   remains	   unknown.	   The	   R103C	  amino	  acid	  substitution	  was	  associated	  with	  increased	  induction	  of	  cell	  death	  in	   cortical	   neurons	   in	   response	   to	   oxygen-­‐glucose	   deprivation	   and	   re-­‐
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oxygenation	  	  13).	  The	  R287Q	  was	  associated	  with	  increased	  plasma	  cholesterol	  levels	   in	   familial	   hypercholesterolemia	   	  14)	   and	   with	   the	   onset	   on	   coronary	  artery	   calcification	   in	   Africa-­‐American	   subjects	   	  15).	   R287Q	   has	   also	   been	  associated	  with	  insulin	  resistance	  in	  type	  2	  diabetic	  patients	  	  16).	  In	  addition,	  in	  human,	   the	   individuals	  which	   have	   a	   Lys55Arg	   variant	   have	   a	   higher	   risk	   of	  coronary	  heart	  diseases	  	  56).	  LPAs	   have	   been	   shown	   to	   function	   as	   substrates	   for	   the	   N-­‐terminal	  phosphatase	  domain	  of	  sEH	  	  4,42).	  The	  functions	  of	  the	  phosphatase	  activities	  of	  sEH	  have	  been	  shown	  to	  include	  argumentation	  of	  the	  cholesterol	  synthesis	  in	  HepG2	  cells	  	  57).	  In	  addition,	  we	  previously	  found	  that	  the	  phosphatase	  activity	  of	  sEH	  suppressed	  VEGF	  levels	  and	  cell	  growth	  in	  Hep3B	  cells	  	  19).	  In	  peritoneal	  mesothelial	   cells,	   LPA	   has	   been	   shown	   to	   induce	   VEGF	   expression	   in	   a	  concentration	   dependent	   manner	   	  58).	   Phosphatase	   activity	   of	   sEH	   has	   been	  linked	  to	  VEGF	  expression,	  but	  there	  is	  no	  evidence	  of	  physiologically	  relevant	  of	  allelic	  variants	  of	  sEH	  in	  VEGF	  expression.	  An	  examination	  of	  the	  actions	  of	  allelic	   variants	   of	   sEH	   on	   LPA	   hydrolysis	   could	   reveal	   other	   biological	  functions	  associated	  with	  the	  phosphatase	  activity.	  	   	  In	  this	  study,	  I	  examined	  the	  mutated	  residues	  of	  sEH	  allelic	  variants	  to	  understand	   the	   effect	   of	   these	   variants	   on	   the	   metabolism	   of	   LPAs.	   These	  investigations	   may	   be	   useful	   for	   further	   clarifying	   the	   role	   of	   sEH	   allelic	  variants	  in	  regulating	  the	  hydrolysis	  of	  LPAs	  in	  vivo.	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II.2	  Materials	  and	  Methods	  
Materials	  	   Stearoyl	   L-­‐α-­‐lysophosphatidic	   acid	   (1-­‐octadecanoyl-­‐sn	   glycero-­‐3-­‐phosphate)	   sodium	   salt	   (s-­‐LPA)	   was	   purchased	   from	   Avanti	   Polar	   Lipids	  (Birmingham,	   AL),	   arachidonoyl	   L-­‐α-­‐lysophosphatidic	   acid	   sodium	   salt	  (arachidonoyl-­‐LPA)	   and	   arachidoyl	   L-­‐α-­‐lysophosphatidic	   acid	   (arachidoyl-­‐LPA)	   were	   obtained	   from	   Echelon	   Biosciences	   Inc.	   (Salt	   Lake,	   UT),	  geranylgeranyl	   pyrophosphate	   ammonium	   salt	   (GGPP)	   was	   obtained	   from	  Sigma	   Chemical	   (St.	   Louis,	   MO),	   and	   sphingosine-­‐1-­‐phosphate	   (S1P)	   was	  kindly	   provided	   by	   Professor	   Katsumura	   of	   Kwansei	   Gakuin	   University.	   3-­‐phenyl-­‐cyano	   (6-­‐methoxy-­‐2-­‐napthalenyl)	   methyl	   ester-­‐2-­‐oxiraneacetic	   acid	  (PHOME)	   was	   purchased	   from	   Cayman	   Chemical	   (Ann	   Arbor,	   MI).	   Trans-­‐stilbene	   oxide	   (t-­‐SO)	   was	   obtained	   from	   Acros	   Organics	   (Fair	   Lawn,	   NJ).	   4-­‐methylumbelliferyl	   phosphate	   (4-­‐MUP)	   was	   obtained	   from	   Wako	   Pure	  Chemicals	  (Osaka,	  Japan).	  
Preparation	  of	  the	  constructs	  of	  allelic	  variants	  of	  sEH	  for	  expression	  in	  
E.	  coli	  	  	   The	   human	  WT	   and	  N-­‐terminal	   domain	   (amino	   acids	   1-­‐221)	   of	   sEH	   in	  pET21a	  vector	  were	  constructed	  as	  described	  previously.	  4)	  The	  primers	  used	  in	  this	  study	  are	  shown	  in	  Table	  II-­‐1.	  For	  the	  construction	  of	  sEH	  variants,	  the	  first	  half	  fragment	  was	  amplified	  with	  the	  primer	  sets	  1	  and	  2	  (K55R),	  1	  and	  3	  (R103C),	   1	   and	   4	   (C154Y),	   1	   and	   5	   (R287Q),	   1	   and	   6	   (V422A),	   and	   1	   and	   7	  (E470G),	  and	  the	  latter	  half	  fragment	  was	  amplified	  with	  the	  primer	  sets	  8	  and	  9	   (K55R),	  8	  and	  10	  (R103C),	  8	  and	  11	  (C154Y),	  8	  and	  12	  (R287Q),	  8	  and	  13	  (V422A),	  and	  8	  and	  14	  (E470G)	  using	  WT	  sEH	  cDNA	  as	  a	   template.	  The	   full-­‐length	  of	  each	  variant	  was	  amplified	  with	  the	  primers	  1	  and	  8	  using	  fragments	  of	  the	  first	  half	  and	  the	  latter	  half	  as	  a	  template,	  and	  inserted	  into	  the	  pET21a	  vector	  with	  NdeI	  and	  XhoI	  sites.	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TABLE	  II-­‐1.	  Primers	  used	  in	  this	  study	  	  
	  
	  No.	   	  Sequences	   	  	  1	   	  5’-­‐GGAATTCCATATGACGCTGCGCGCGGCCGT-­‐3’	   	  Forward	   primer:	   1st-­‐20th	   nucleotides;	   the	  
NdeI	  site	  is	  underlined	  and	  the	  start	  codon	  is	  double-­‐underlined	  2	   5’-­‐AGTGTGATCTCTCCTCTCATAAGCCGGGTAG-­‐3’	   Reverse	   primer:	   149th-­‐179th	   nucleotide;	  mutation	  T	  to	  C	  is	  underlined	  3	   5’-­‐CCTGGAGCATGGGGCAGTTGATCTTTCTGGC-­‐3’	   Reverse	   primer:	   292nd-­‐322nd	   of	  nucleotide;	   mutation	   of	   G	   to	   A	   is	  underlined	  4	   5’-­‐ACCATTCCCACCTGATACGACTCTATCAGGA-­‐3’	   Reverse	   primer:	   446th-­‐476th	   nucleotide;	  mutation	  of	  C	  to	  T	  is	  underlined	  5	   5’-­‐GGTAACCTGCCTGGGCCAGA-­‐3’	   Reverse	  primer:	  840th-­‐859th	  nucleotide	  
6	   5’-­‐CTTTATGCATGGATAAAAC-­‐3’	   Reverse	  primer:	  1246th-­‐1264th	  nucleotide	  
7	   5’-­‐CCATGTTTCGGTACCAGTTT-­‐3’	   Reverse	  primer:	  1389th-­‐1408th	  nucleotide	  
8	   5’-­‐ATACTCGAGCATCTTTGAGACCACCGGTG-­‐3’	   Reverse	  primer:	  1646th-­‐1665th	  nucleotide;	  
XhoI	  site	  is	  underlined	  9	   5’-­‐AGGAGAGATCACACTTTCCC-­‐3’	   Forward	  primer:	  165th-­‐184th	  nucleotide	  
10	   5’-­‐CCCCATGCTCCAGGCAGCTC-­‐3’	   Reverse	  primer:	  309th-­‐328th	  nucleotide	  
11	   5’-­‐CCAGGCAGGTTACCAGGTCCTAGCTATGGA-­‐3’	   Forward	   primer:	   846th-­‐875th	   nucleotide;	  mutation	  of	  G	  to	  A	  is	  underlined	  12	   5’-­‐TCAGGTGGGAATGGTCAAAC-­‐3’	   Forward	  primer:	  462nd-­‐481st	  nucleotide	  
13	   5’-­‐TATCCATGCATAAAGCCTGTGAAGCGGGAGG-­‐3’	   Forward	   primer:	   1249th-­‐1280th	  nucleotide;	   mutation	   of	   T	   to	   C	   is	  underlined	  14	   5’-­‐GGTACCGAAACATGGGAAGGAACTGGAAGTG-­‐3’	   Forward	   primer:	   1394th-­‐1424th	  nucleotide;	   mutation	   of	   A	   to	   G)	   is	  underlined	  15	   5’-­‐ATAGCGCGCGACCTCTTGCAATCCAAGTG-­‐3’	   Forward	   primer:	   686th-­‐706th	   nucleotide;	  
BssHII	  site	  is	  underlined	  16	   5’-­‐AAACTCGAGAAGCTGGATTCCGGTCACTT-­‐3’	   Reverse	   primer:	   644th-­‐663th	   nucleotide;	  
XhoI	  site	  is	  underlined	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   For	  construction	  of	  the	  C-­‐terminal	  domain	  of	  sEH	  (amino	  acids	  230-­‐555),	  the	   fragment	  was	  amplified	  with	  the	  primers	  15	  and	  16,	  and	  connected	  after	  the	  N-­‐terminal	  1st-­‐5th	  amino	  acids	  of	   sEH	  with	  a	  BssHII	  site.	  The	  N-­‐terminal	  allelic	  variants	  of	   sEH	   (N-­‐K55R,	  N-­‐R103C,	  N-­‐C154Y)	  were	  amplified	  with	   the	  primers	  1	  and	  16	  using	  each	  allelic	  variant	  of	  full-­‐length	  sEH	  as	  a	  template,	  and	  inserted	   into	  the	  pET21a	  vector.	  The	  C-­‐terminal	  allelic	  variants	  of	  sEH	  in	   the	  pET21a	  vector	  (C-­‐R287Q,	  C-­‐V422A,	  and	  C-­‐E470G)	  were	  prepared	  by	  insertion	  of	  the	  mutation	  into	  the	  C-­‐terminal	  domain	  of	  sEH	  in	  the	  same	  way	  as	  for	  the	  full-­‐length	  variants	  of	   sEH.	  The	  WT	  and	  all	   variants	  of	   the	   sEH	  protein	  were	  expressed	   in	  E.	  coli	   (BL21(DE3)codon+)	   for	  24	  h	   at	   250C.	  The	  proteins	  were	  purified	  with	  an	  Ni-­‐NTA	  agarose	  column	  (Qiagen,	  Hilden,	  Germany)	  according	  to	  the	  manufacturer’s	  instructions.	  The	  purified	  proteins	  were	  dialyzed	  against	  50	  mM	  Tris-­‐HCL	  buffer,	  pH	  7.5.	  	  
Cell	  culture	  and	  expression	  	  	   The	  full-­‐length	  WT	  or	  allelic	  variants	  of	  sEH	  (WT,	  K55R,	  R103C,	  C154Y,	  R287Q,	   V422A,	   and	   E470G)	   were	   ligated	   into	   BamHI/EcoRI	   sites	   of	   the	  pcDNA3.1(+)	  vector	   (Invitrogen).	  The	  pcDNA	  plasmids	   containing	   sEH	  allelic	  variants	   were	   transfected	   into	   Hep3B	   cells,	   and	   the	   transfected	   cells	   were	  selected	   by	   G418.	   Total	   RNA	   was	   extracted	   from	   cells	   with	   Isogen	  (Nippongene,	   Toyama,	   Japan)	   according	   to	   the	   manufacturer's	   instructions,	  and	   converted	   to	   cDNA	   by	   reverse-­‐transcription	   using	   RevertAid	   reverse	  transcriptase	   (Thermo,	   Pittsburgh	   PA,	   USA).	   Real-­‐time	   PCR	   was	   performed	  with	   SYBR	   premix	   Ex	   Taq	   II	   (Takara,	   Shiga,	   Japan)	   following	   the	  manufacturer's	   instructions.	  PCR	  was	  performed	  using	  a	  Thermal	  Cycler	  Dice	  Real	  Time	  System	  Single	  TP850	  (Takara,	  Shiga,	  Japan).	  The	  primers	  for	  human	  
VEGF	   (Acc	   No.	   NM_	   AF022375)	   were	   5’-­‐TTCATGGATGTCTATCAGCG-­‐3’	  (forward)	   and	   5’-­‐CATCTCTCCTATGTGCTGGC-­‐3’	   (reverse).	   The	   primers	   for	  human	   histone-­‐H4	   (Acc	   No.	   NM_003548)	   were	   5’-­‐
	   36	  
TATCGGGCTCCAGCGGTCATGTC-­‐3’	   (forward)	   and	   5’-­‐GGATCGAAACGTGCAAAGCTGGAG-­‐3’	  (reverse).	  
Phosphatase	  activity	  assay	  and	  kinetics	  	   Phosphate	  release	  was	  detected	  by	  the	  Biomol	  green	  assay.	  The	  Biomol	  green	   assay	   kit	   was	   purchased	   from	   Enzo	   Life	   Sciences	   (Plymouth	  Meeting,	  PA)	  and	  the	  assay	  was	  performed	  according	  to	  the	  manufacturer’s	  instructions.	  Purified	  human	  sEH	  allelic	  variants	  (9.5	  pmol)	  were	  pre-­‐incubated	  for	  5	  min	  at	  370C	  in	  25	  mM	  Bis	  Tris-­‐HCl	  buffer,	  pH	  7.0,	  containing	  1	  mM	  MgCl2	  and	  0.01%	  Bovine	   Serum	   Albumin	   (BSA).	   Each	   substrate	   was	   added	   at	   the	   final	  concentration	   of	   10	   µM	   and	   incubated	   for	   5	   min	   at	   370C.	   The	   reaction	   was	  stopped	   by	   the	   addition	   of	   Biomol	   green	   reagent	   and	   held	   at	   room	  temperature	   for	   60	   min.	   The	   resulting	   green	   color	   was	   measured	   by	   an	  EnVision	   2104	  Multilabel	   Reader	   (Perkin	   Elmer,	   Foster	   City,	   CA)	   at	   630	   nm.	  For	   comparison	   with	   the	   synthetic	   substrate,	   phosphatase	   activity	   was	  measured	  using	  4-­‐MUP	  in	  25	  mM	  Bis	  Tris-­‐HCl	  buffer,	  pH	  7.0,	  containing	  1	  mM	  MgCl2	   and	   0.01%	   BSA.	   Purified	   full-­‐length	   sEH	   (80	   pmol)	   or	   N-­‐terminal	  domain	  variants	  (80	  pmol)	  were	  used.	  The	  reaction	  was	  started	  by	  addition	  of	  4-­‐MUP	  at	  a	  concentration	  of	  0.5	  mM.	  The	  reaction	  was	  performed	  at	  370C	  for	  up	   to	   60	   min	   and	   the	   fluorescence	   intensity	   of	   the	   produced	   4-­‐methylumbelliferone	   was	   measured	   every	   5	   min	   by	   an	   EnVision	   2104	  Multilabel	   Reader	   at	   an	   excitation	   wavelength	   of	   330	   nm	   and	   emission	  wavelength	   of	   465	   nm.	   For	   the	   determination	   of	   kinetic	   parameters	   of	   sEH	  variants,	  phosphatase	  activities	  toward	  stearoyl-­‐LPA	  (final	  concentration:	  2,	  4,	  8,	  15	  and	  20	  µM)	  were	  measured,	  and	  the	  Km	  and	  Vmax	  were	  obtained	  using	  Prism	  Graphpad	  enzyme	  kinetic	  software	  as	  described	  previously	  	  4).	  
Epoxide	  hydrolase	  activity	  assay	  	   Epoxide	   hydrolase	   activities	   of	   the	   full-­‐length	   and	   C-­‐terminal	   allelic	  variants	  of	  sEH	  were	  measured	  with	  a	   fluorescent	  substrate,	  PHOME	   	  59).	  The	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full-­‐length	  (1.6	  pmol)	  and	  C-­‐terminal	  domain	  (1.6	  pmol)	  of	  sEH	  were	  reacted	  with	  25	  μM	  PHOME	   in	  25	  mM	  Bis	  Tris-­‐HCL	  buffer,	  pH	  7.0,	   containing	  0.01%	  BSA	   at	   300C.	   The	   reaction	   mixture	   was	   analyzed	   by	   an	   Envision	   2104	  Multilabel	  Reader	  every	  1	  min	  for	  30	  min	  at	  an	  excitation	  wavelength	  of	  330	  nm	   and	   emission	   wavelength	   of	   465	   nm.	   The	   fluorescence	   intensity	   of	   the	  reaction	  product,	  6-­‐metoxy-­‐2-­‐naphthaldehyde	  (6-­‐MNA),	  was	  determined	  with	  a	  calibration	  curve	  prepared	  with	  the	  authentic	  6-­‐MNA.	  The	  epoxide	  hydrolase	  activities	  of	   the	   full-­‐length	  variants	  and	  C-­‐terminal	  variants	  of	  sEH	  were	  also	  measured	  using	  t-­‐SO	  as	  a	  substrate	  by	  HPLC.	  The	  purified	  proteins	  of	  the	  full-­‐length	  variants	  (0.48	  nmol)	  and	  C-­‐terminal	  variants	  (0.48	  nmol)	  of	  sEH	  were	  incubated	  with	  t-­‐SO	  (50	  μM)	  in	  25	  mM	  Bis	  Tris-­‐HCl	  buffer	  (pH	  7.0)	  containing	  BSA	  (0.1	  mg/ml)	   for	  15	  min	  at	  370C.	  The	  enzymatic	  reaction	  was	  stopped	  by	  addition	  of	  ethyl	  acetate	  (1	  ml).	  After	  centrifugation	  at	  4,000	  rpm	  for	  10	  min,	  the	  upper	  organic	  layer	  was	  transferred	  to	  a	  new	  tube	  and	  evaporated	  under	  nitrogen.	  The	  resulting	  residues	  were	  dissolved	  in	  75%	  methanol	  and	  analyzed	  by	  HPLC	  using	  a	  TSKgel	  ODS-­‐100V	  (4.6	  mm	  I.D.	  x	  15	  cm;	  Tosoh,	  Tokyo,	  Japan).	  To	   detect	   t-­‐SO	  metabolites,	  mobile	   phase	  A	   (water:	   acetic	   acid,	   100:0.1)	   and	  mobile	   phase	  B	   (acetonitrile:	   acetic	   acid,	   100:0.1)	  were	   used.	   The	  HPLC	  was	  run	  at	  a	  flow	  rate	  of	  0.7	  ml/min,	  with	  a	  linear	  gradient	  from	  30%	  A	  to	  100%	  B	  for	   30	   min.	   The	   amount	   of	   produced	   t-­‐SO	   diol	   was	   determined	   with	   a	  calibration	   curve	   prepared	   with	   the	   authentic	   t-­‐SO	   diol	   (Sigma-­‐Aldrich,	   St.	  Louis,	  MO).	  
Statistical	  analysis	  	   All	  experiments	  were	  repeated	  at	  least	  three	  times	  with	  three	  replicates	  in	   each	   experiment.	   A	   Student’s	   t-­‐test	   was	   used	   for	   comparing	   the	   levels	   of	  each	  activity.	  
	  
	  
	   38	  
II.3	  Results	  
Epoxide	  hydrolase	  activity	  of	  sEH	  allelic	  variants	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Fig.	   II-­‐1	  Epoxide	  hydrolase	  activities	  of	  sEH	  allelic	  variants	  toward	  t-­‐SO	  and	  PHOME.	  (A)	   The	   full-­‐length	   (0.48	   nmol)	   and	   C-­‐terminal	   domain	   (0.48	   nmol)	   of	   sEH	   allelic	  variants	   purified	   protein	  were	   reacted	  with	   t-­‐SO	   (50	   µM)	   at	   370C	   for	   15	  min,	   then	  analyzed	  by	  HPLC.	  (B)	  The	  full-­‐length	  (1.6	  pmol)	  and	  C-­‐terminal	  domain	  (1.6	  pmol)	  of	  sEH	  allelic	  variants	  were	  reacted	  with	  PHOME	  (25	  µM)	  at	  300C.	  EH,	  epoxide	  hydrolase.	  Values	  are	  given	  as	   the	  mean	  for	   three	  replicate	  experiments.	  **p<0.01,	  significantly	  different	  from	  WT	  sEH.	  	   As	  a	  result,	  the	  C-­‐terminal	  allelic	  variant	  C-­‐R287Q	  showed	  significantly	  lower	   activity	   than	   that	   of	   the	  WT	   C-­‐terminal	   domain	   of	   sEH.	   On	   the	   other	  hand,	   the	   epoxide	   hydrolase	   activities	   of	   the	   full-­‐length	   R103C	   and	   R287Q	  toward	   PHOME	   were	   lower	   than	   that	   of	   the	   WT	   (Fig.	   II-­‐1B).	   C-­‐R287Q	   also	  showed	  significantly	  lower	  activity	  than	  that	  of	  the	  WT.	  	  
Phosphatase	  activity	  of	  sEH	  allelic	  variants	  toward	  4-­‐MUP	  






























































































Fig.	  II-­‐2	  Phosphatase	  activities	  of	  sEH	  allelic	  variants	  toward	  4-­‐MUP.	  Full-­‐length	  and	  N-­‐terminal	  domain	  of	  sEH	  allelic	  variants	   (80	  pmol)	  were	   incubated	  with	  4-­‐MUP	  (0.5	  mM),	  and	  the	  fluorescence	  of	  the	  hydrolyzed	  product	  was	  measured	  every	   1	  min	   for	   60	  min	   at	   330	   nm	   (Ex)	   and	   465	   nm	   (Em).	   Values	   are	   given	   as	   the	  mean	  for	  three	  replicate	  experiments.	  **p<0.01,	  significantly	  different	  from	  WT	  sEH.	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Fig.	  II-­‐4	  Phosphatase	  activities	  of	  the	  N-­‐terminal	  allelic	  variants	  of	  sEH	  towards	  LPAs,	  GGPP,	  and	  S1P.	  The	  N-­‐terminal	  allelic	  variant	  of	  sEH	  (9.5	  pmol)	  was	   incubated	  with	  10	   μM	   stearoyl-­‐LPA	   (A),	   arachydonoyl-­‐LPA	   (B),	   arachidoyl-­‐LPA	   (C),	   GGPP	   (D),	   and	  S1P	  (E).	  The	  released	  phosphate	  was	  detected	  with	  malachite	  green.	  Values	  are	  given	  as	   the	   mean	   ±	   SD	   for	   three	   separate	   experiments.	   **p<0.01,	   significantly	   different	  from	  the	  WT	  sEH.	  	  
VEGF	  mRNA	  levels	  in	  Hep3B	  cells	  overexpressing	  sEH	  allelic	  variants	  	   Previously	  our	  laboratory	  found	  that	  WT	  sEH	  suppressed	  VEGF	  mRNA	  levels	   in	  Hep3B	  cells,	   and	   the	  phosphatase	  domain	  of	   sEH	  was	  necessary	   for	  the	   suppression	  19).	   Therefore,	   I	   next	   examined	   the	   effect	   of	   amino	   acid	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Fig.	  II-­‐5	  VEGF	  expression	  in	  the	  cells	  overexpressing	  the	  sEH	  allelic	  variants	  (A)	   The	   overexpression	   of	   the	   WT	   or	   allelic	   variants	   of	   sEH	   in	   Hep3B	   cells	   was	  confirmed	  by	  western	  blotting	  with	   anti-­‐sEH	  antibody.	   (B)	  VEGF	  mRNA	   levels	  were	  analyzed	   by	   real-­‐time	   PCR.	   The	   ratio	   of	  VEGF	   to	  histone-­‐H4	  mRNA	   in	  mock-­‐treated	  cells	  was	  set	  at	  1.	  VEGF:	  vascular	  endothelial	  growth	  factor.	  Values	  are	  the	  mean	  ±	  S.D.	  for	  three	  separate	  experiments.	  **p<0.01,	  significantly	  different	  from	  mock	  treatment.	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Kinetic	  determination	  of	  allelic	  variants	  toward	  LPA	  	   Next,	  the	  kinetic	  parameters	  of	  sEH	  allelic	  variants	  toward	  stearoyl-­‐LPA	  were	   determined	   (Table	   II-­‐2).	   R103C	   and	  R287Q	   showed	   significantly	   lower	  
Vmax	   values	   than	   the	  WT	   sEH,	   while	   km	   values	   of	   these	   variants	   were	   not	  significantly	  different	   from	  that	  of	  WT.	  R103C	  and	  R287Q	  also	  showed	  lower	  
Vmax/Km	  ratios	  than	  the	  WT	  or	  other	  allelic	  variants	  of	  sEH	  (Fig.	  II-­‐6).	  	  
TABLE	  II-­‐2.	  Kinetic	  analysis	  of	  sEH	  allelic	  variants	  towards	  stearoyl-­‐LPA	  	  
	  	   Km	  (μM)	   Vmax	  	  (nmol/min/nmol	  protein)	   Vmax/Km	  	   	   	   	  WT	   12.1	  ±	  2.1	   	  12.1	  ±	  1.0	   1.00	  K55R	   	  8.9	  ±	  1.8	   	  	  7.9	  ±	  0.7	   0.89	  R103C	   	  7.2	  ±	  1.2	   	  	  3.4	  ±	  0.2	   0.47	  C154Y	   12.9	  ±	  2.7	   	  11.6	  ±	  1.2	   0.90	  R287Q	   	  8.9	  ±	  0.7	   	  	  5.1	  ±	  0.3	   0.57	  V422A	   	  9.1	  ±	  1.9	   	  	  7.2	  ±	  0.7	   0.79	  E470G	   16.7	  ±	  3.3	   	  15.1	  ±	  1.6	   0.90	  
	  	   	  	   	  	   	  	  The	  phosphatase	  activities	  of	  sEH	  allelic	  variants	  toward	  stearoyl-­‐LPA	  were	  detected	  by	  malachite	  green,	  and	  the	  kinetic	  parameters	  of	  sEH	  allelic	  variants	  were	  analyzed.	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II.4	  Discussion	  
	   In	   a	   previous	   study,	   we	   found	   that	   LPAs	  were	   good	   substrates	   for	   the	  phosphatase	   activity	   of	   sEH	   	  4).	   In	   this	   study,	   I	   examined	   the	   metabolism	   of	  LPAs	   by	   allelic	   variants	   of	   human	   sEH.	   In	   the	   kinetic	   study,	   the	   R103C	   and	  R287Q	  had	  lower	  Vmax/Km	  ratios	  toward	  stearoyl-­‐LPA	  than	  WT.	  In	  regard	  to	  the	   role	   of	   arginine	   residue,	   a	   crystal	   structure	   of	   mouse	   sEH	   showed	   that	  Arg285	   (287	   in	  human)	   forms	  an	   inter-­‐monomer	   ionic	  salt	  bridge	  with	  Glu252,	  and	  such	  salt-­‐bridges	  are	  known	  to	  play	  an	  important	  role	  in	  protein	  structure	  and	  stabilization	  10).	  R103C	  and	  R287Q	  have	  been	   implicated	   in	  susceptibility	  to	   cardiovascular	   disease	   and	   stroke	   outcomes	  13,14).	   The	   allelic	   frequency	   of	  these	   variants	   was	   observed	   for	   diseases-­‐susceptibility	   in	   African-­‐American	  and	   Asian	   individuals	   including	   Japanese	   population.	   The	   greater	   allelic	  frequency	  of	  R103C	  and	  R287Q	  is	  approximately	  17%	  in	  African-­‐American	  and	  21%	   in	   Asian	   individuals,	   respectively	  9,60,61).	   In	   this	   study,	   phosphatase	  activity	  of	  sEH	  toward	  arachidoyl-­‐LPA	  was	  lower	  than	  those	  toward	  stearoyl-­‐LPA	  and	  arachidonoyl-­‐LPA.	  Despite	  the	  difference	  of	  only	  two-­‐carbon	  length	  of	  acyl	   chain	   between	   arachidoyl-­‐	   and	   stearoyl-­‐LPA,	   arachidoyl-­‐LPA	  which	   has	  longer	  acyl	  chain	  might	  not	  be	  able	  to	  fit	  the	  active	  pocket	  of	  sEH.	  On	  the	  other	  hand,	   compact	   molecular	   structure	   of	   arachidonoyl-­‐LPA	   which	   has	  unsaturated	  acyl	  chain	  might	  result	  in	  fit	  to	  the	  active	  pocket	  of	  sEH.	  Due	  to	  the	  lower	   basal	   activity	   of	   full-­‐length	   sEH	   toward	   arachidoyl-­‐LPA,	   R103C	   and	  R287Q	   might	   not	   suppress	   the	   activity.	   sEH	   showed	   higher	   phosphatase	  activity	   toward	   LPAs	   than	   GGPP	   and	   S1P,	   suggesting	   that	   lyso-­‐glycerophospholipids	   are	   specific	   substrates	   for	   the	   phosphatase	   activity	   of	  sEH.	  	  	   The	  catalytic	  activities	  of	   sEH	  reported	  so	   far	  can	  be	  explained	  by	   the	  action	  of	   the	  N/C-­‐terminal	   domain	   alone	  62).	  In	   this	   study,	   the	   full-­‐length	   and	  the	   N-­‐terminal	   domain	   alone	   of	   sEH	   displayed	   phosphatase	   activity	   toward	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LPAs.	   The	   full-­‐length	   and	   the	   C-­‐terminal	   domain	   alone	   of	   sEH	   displayed	  epoxide	   hydrolase	   activity	   toward	   PHOME.	   These	   findings	   suggest	   that	   the	  presence	  of	  a	  phosphatase	  domain	  did	  not	  affect	  the	  epoxide	  hydrolase	  activity	  and	  the	  presence	  of	  epoxides	  hydrolase	  domain	  did	  not	  affect	  the	  phosphatase	  activity,	  indicating	  that	  both	  catalytic	  domain	  act	  independently.	  	  	   In	  the	  current	  investigation,	  I	  found	  that	  the	  epoxide	  hydrolase	  activity	  of	  sEH	   toward	   PHOME	   was	   more	   sensitive	   to	   the	   amino	   acid	   substitution	   of	  allelic	   variants	   than	   that	   toward	   t-­‐SO.	   I	   consider	   that	   epoxide	   hydrolase	  activity	   toward	   t-­‐SO	   was	   hardly	   affected	   by	   the	   changes	   in	   the	   structure	   of	  active	  pocket	  by	  amino	  acid	  substitution,	  because	  molecular	  size	  of	   t-­‐SO	  was	  smaller	   than	   that	   of	   PHOME.	   The	   R103C	   and	   R287Q	   had	   significantly	   lower	  epoxide	  hydrolase	   activity	   toward	  PHOME	   than	  WT	   sEH.	  The	   substitution	  of	  K55R	  and	  C154Y	  also	   slightly	  decreased	   epoxide	  hydrolase	   activity	   although	  these	   substitutions	   were	   present	   in	   N-­‐terminal	   domain.	   Reduced	   epoxide	  hydrolase	   activity	   of	  mouse	   R103C	   sEH	   due	   to	   its	   unstable	   structure	   by	   the	  disruption	   of	   salt	   bridge	   with	   W142	   has	   been	   suggested	   by	   Przybyla-­‐Zawislak	  9).	   In	   the	   independent	   N/C-­‐domains,	   some	   variants	   had	   similar	  activity	   when	   compared	   with	   the	   full-­‐length	   of	   sEH,	   suggesting	   that	   these	  domains	  are	  independent	  of	  each	  other.	  	  	   In	   conclusion,	   I	   found	   that	   the	   in	  vitro	   enzymatic	   activity	  of	  R103C	  or	  R287Q	   of	   sEH	   allelic	   variants	   was	   significantly	   different	   from	   WT	   on	   LPA	  hydrolysis	  and	  this	  may	  contribute	  to	  some	  of	  the	  pathologies	  associated	  with	  such	  polymorphisms	   studies.	   Previously	   it	  was	   found	   that	   overexpression	   of	  sEH	  suppressed	  VEGF	  expression	  in	  Hep3B	  cells,	  and	  the	  phosphatase	  activity	  was	   important	   in	   the	   suppression	   	  19).	   However,	   the	   in	   vivo	   investigations	  revealed	  that	  all	  allelic	  variants	  of	  sEH	  used	  in	  this	  experiment,	  except	  V442A,	  showed	  VEGF-­‐suppressive	  effects	  similar	  to	  those	  of	  the	  WT	  sEH.	  These	  results	  suggest	   that	   the	  phosphatase	  activities	  of	   the	  sEH	  variants	  were	  sufficient	   to	  suppress	  the	  VEGF	  levels,	  even	  though	  these	  activities	  were	  lower	  than	  that	  of	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General	  conclusion	  	  	   In	  Chapter	  I,	  I	  characterized	  the	  frog	  homolog	  (Xenopus	  laevis)	  of	  human	  sEH	   and	   suggested	   the	   possible	   role	   of	   Xenopus	   sEH	   in	   the	   embryonic	  developmental.	   In	   situ	   hybridization	   and	   immunohistochemistry	   showed	   the	  sEH	  gene	  expression	  patterns	  during	  embryonic	  development,	  and	  in	  various	  tissues	   the	   expression	   was	   investigated	   both	   at	   the	   transcript	   and	   protein	  levels.	   In	   addition,	   the	   endogenous	  EETs,	   a	   substrate	  of	   sEH	  was	  detected	   in	  
Xenopus	   liver.	   The	   human	   chimeras	   and	  mutants	   could	   explain	   the	   frog	   sEH	  has	  some	  different	   function	  with	   the	  human	  sEH.	   I	  also	  proved	  that	   frog	  sEH	  still	  be	   found	   to	  regulate	  epoxy	   fatty	  acid	   in	  vivo	  by	   in	  vitro	  determination	  of	  sEH	  endogenous	  substrates	  of	  11,12-­‐EET	  and	  14,15-­‐EET	  in	  frog	  tissues	  using	  LC-­‐MS	  assay.	  EETs	  and	  sEH	  epoxide	  hydrolase	  activity	  seem	  to	  be	   important	  for	  development	  of	  Xenopus,	  but	  the	  phosphatase	  activity	  does	  not	  because	  the	  
Xenopus	   sEH	   did	   not	   have	   phosphatase	   activity.	   This	   work	   is	   important	  knowledge	  and	  useful	  tool	  for	  further	  investigations	  on	  the	  development	  study	  of	  Xenopus	  sEH.	  	  	   In	   Chapter	   II,	   the	   LPAs	   metabolism	   and	   VEGF	   expression	   by	   allelic	  variants	   of	   human	   sEH	   were	   examined	   by	   expressing	   in	   Hep3B	   cells.	   As	   a	  result,	  five	  of	  six	  allelic	  variants	  suppressed	  VEGF	  mRNA	  levels	  in	  Hep3B	  cells,	  and	  R103C	  or	  R287Q	  variant	  showed	  lower	  phosphatase	  activity	  toward	  LPAs.	  The	   data	   of	   VEGF-­‐suppressive	   effect	   and	   the	   LPAs	   metabolism	   by	   the	   sEH	  allelic	   variants	   are	   the	   important	   finding	   in	   this	   study.	   These	   results	   may	  contribute	   to	   understanding	   the	   enzyme	   function	   for	   human	   diseases	   to	  develop	  drugs,	  and	  the	  possible	  role	   in	   future	   investigation	  of	  developmental	  study.	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Abbreviations	  	  	  sEH,	  soluble	  epoxide	  hydrolase	  	  CYP	  P450,	  cytochrome	  P450	  EET,	  epoxyeicosatreienoic	  acid	  DHET,	  dihydroxyeicosatrienoic	  acid	  WISH,	  whole-­‐mount	  in	  situ	  hybridization	  sLPA,	  stearoyl	  L-­‐α-­‐lysophosphatidic	  acid	  	  arachidonoyl	   LPA,	   arachidonoyl	   L-­‐α-­‐lysophosphatidic	   acid	   arachidoyl	   LPA,	  arachidoyl	  L-­‐α-­‐lysophosphatidic	  acid	  GGPP,	  geranylgeranyl	  pyrophosphate	  	  S1P,	  sphingosine-­‐1-­‐phosphate	  	  RT-­‐PCR,	  reverse-­‐transcription	  polymerase	  chain	  reaction	  VEGF,	  vascular	  endothelial	  growth	  factor	  	  4-­‐MUP,	  4-­‐methylumbelliferyl	  phosphate	  	  PHOME,	  3-­‐phenyl-­‐cyano	  methyl	  ester-­‐2-­‐oxiraneacetic	  acid	  	  
t-­‐SO,	  trans	  stilbene	  oxide.	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